3,587 results on '"APH - Amsterdam Public Health"'
Search Results
2. Prevention and public health approaches to trauma and traumatic stress: a rationale and a call to action
- Author
-
Siri Thoresen, Miranda Olff, Kathryn M. Magruder, Nancy Kassam-Adams, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Adult Psychiatry, and APH - Amsterdam Public Health
- Subjects
medicine.medical_specialty ,lcsh:RC435-571 ,Poison control ,Suicide prevention ,Occupational safety and health ,03 medical and health sciences ,0302 clinical medicine ,Nursing ,prevention ,lcsh:Psychiatry ,Medicine ,030212 general & internal medicine ,Psychiatry ,business.industry ,Public health ,public health ,Traumatic stress ,Societal impact of nanotechnology ,Posttraumatic stress disorder ,trauma ,030227 psychiatry ,Call to action ,Professional association ,business ,Proceedings Paper - Abstract
Background : The field of trauma and traumatic stress is dominated by studies on treatments for those who experience adversity from traumatic experiences. While this is important, we should not neglect the opportunity to consider trauma in a public health perspective. Such a perspective will help to develop prevention approaches as well as extend the reach of early interventions and treatments. The purpose of this paper is to provide an introduction to a public health approach to trauma and traumatic stress and identify key opportunities for trauma professionals and our professional societies (such as the International Society for Traumatic Stress Studies [ISTSS] and the European Society for Traumatic Stress Studies [ESTSS]) to increase our societal impact by adopting such an approach. Method : This paper reviews and summarizes key findings related to the public health impact of trauma. The special case of children is explored, and a case example of the Norwegian terrorist attacks in 2011 illustrates the potential for improving our response to community level traumatic events. We also discuss how professional organizations such as ESTSS and ISTSS, as well as individual trauma professionals, can and should play an important role in promoting a public health approach. Results : Trauma is pervasive throughout the world and has negative impacts at the personal, family, community, and societal levels. A public health perspective may help to develop prevention approaches at all of these levels, as well as extend the reach of early interventions and treatments. Conclusions : Professional organizations such as ESTSS and ISTSS can and should play an important role in promoting a public health approach. They should promote the inclusion of trauma in the global public health agenda and include public health in their activities. Keywords: Posttraumatic stress disorder; trauma; prevention; public health (Published: 18 March 2016) Responsible Editor: Marit Sijbrandij, VU University, Netherlands. This paper is part of the Special Issue: Trauma occurs in social contexts. More papers from this issue can be found at www.ejpt.net For the abstract or full text in other languages, please see Supplementary files in the column to the right (under ‘Article Tools’). Citation: European Journal of Psychotraumatology 2016, 7 : 29715 - http://dx.doi.org/10.3402/ejpt.v7.29715
- Published
- 2023
- Full Text
- View/download PDF
3. Impact of the COVID-19 outbreak on acute stroke care
- Author
-
Jonathan M. Coutinho, Jessica Burggraaff, Leon A. Rinkel, S. M. van Schaik, Mieke C. Brouwer, J. C. M. Prick, R. E. R. Slot, Marieke C. Visser, Charles B. L. M. Majoie, Bart J. Emmer, D. van de Beek, Adrien E. Groot, N. M. A. Sombroek, Yvo B.W.E.M. Roos, R M Van den Berg-Vos, Ludo F. M. Beenen, Graduate School, ANS - Neurovascular Disorders, Radiology and Nuclear Medicine, Neurology, ACS - Atherosclerosis & ischemic syndromes, AII - Infectious diseases, ANS - Neuroinfection & -inflammation, AII - Amsterdam institute for Infection and Immunity, ANS - Amsterdam Neuroscience, APH - Amsterdam Public Health, ACS - Microcirculation, ACS - Pulmonary hypertension & thrombosis, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, and ARD - Amsterdam Reproduction and Development
- Subjects
Male ,Emergency Medical Services ,medicine.medical_specialty ,Neurology ,medicine.medical_treatment ,Clinical Neurology ,Acute care ,Time-to-Treatment ,symbols.namesake ,Reperfusion therapy ,medicine ,Humans ,Thrombolytic Therapy ,Poisson Distribution ,Poisson regression ,Pandemics ,Stroke ,Aged ,Ischemic Stroke ,Netherlands ,Quality of Health Care ,Retrospective Studies ,Thrombectomy ,Neuroradiology ,Aged, 80 and over ,Original Communication ,business.industry ,Incidence ,COVID-19 ,Outbreak ,Thrombolysis ,Middle Aged ,medicine.disease ,Quality ,Hospitalization ,Treatment Outcome ,Emergency medicine ,Reperfusion ,symbols ,Female ,Neurology (clinical) ,business - Abstract
Background and purpose There are concerns that the coronavirus disease 2019 (COVID-19) outbreak negatively affects the quality of care for acute cardiovascular conditions. We assessed the impact of the COVID-19 outbreak on trends in hospital admissions and workflow parameters of acute stroke care in Amsterdam, The Netherlands. Methods We used data from the three hospitals that provide acute stroke care for the Amsterdam region. We compared two 7-week periods: one during the peak of the COVID-19 outbreak (March 16th–May 3th 2020) and one prior to the outbreak (October 21st–December 8th 2019). We included consecutive patients who presented to the emergency departments with a suspected stroke and assessed the change in number of patients as an incidence-rate ratio (IRR) using a Poisson regression analysis. Other outcomes were the IRR for stroke subtypes, change in use of reperfusion therapy, treatment times, and in-hospital complications. Results During the COVID-19 period, 309 patients presented with a suspected stroke compared to 407 patients in the pre-COVID-19 period (IRR 0.76 95%CI 0.65–0.88). The proportion of men was higher during the COVID-19 period (59% vs. 47%, p p = 0.58) or endovascular thrombectomy (11% vs 12%, p = 0.82) or associated treatment times. Seven patients (all ischemic strokes) were diagnosed with COVID-19. Conclusion We observed a 24% decrease in suspected stroke presentations during the COVID-19 outbreak, but no evidence for a decrease in quality of acute stroke care.
- Published
- 2021
4. Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis
- Author
-
Evelien Dekker, Victorine H. Roos, Barbara A. J. Bastiaansen, Paul Fockens, Patrick M.M. Bossuyt, Arthur S. Aelvoet, Frank G. J. Kallenberg, Gastroenterology and Hepatology, Graduate School, APH - Methodology, APH - Personalized Medicine, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Epidemiology and Data Science, APH - Amsterdam Public Health, and CCA -Cancer Center Amsterdam
- Subjects
Adenoma ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Perforation (oil well) ,Familial adenomatous polyposis ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Duodenal Neoplasms ,Interquartile range ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Adverse effect ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Endoscopy ,Middle Aged ,medicine.disease ,Polypectomy ,Surgery ,Adenomatous Polyposis Coli ,030220 oncology & carcinogenesis ,Pancreatitis ,030211 gastroenterology & hepatology ,Duodenal cancer ,business - Abstract
Background and Aims Almost all patients with familial adenomatous polyposis (FAP) develop duodenal adenomas, with a 4% to 18% risk of progression into duodenal cancer. Prophylactic endoscopic resection of duodenal adenomas may prevent cancer and is considered safer than surgical alternatives; however, data are limited. Therefore, the aim of this study was to assess safety and effectiveness of endoscopic duodenal interventions in patients with FAP. Methods We performed a historical cohort study including patients with FAP who underwent an endoscopic duodenal intervention between 2002 and 2018. Safety was defined as adverse event rate per intervention and effectiveness as duodenal surgery–free and duodenal cancer–free survival. Change in Spigelman stage was assessed as a secondary outcome. Results In 68 endoscopy sessions, 139 duodenal polypectomies were performed in 49 patients (20 men; median age, 43). Twenty-nine patients (14 men; median age, 49) underwent a papillectomy. After polypectomy, 9 (13%) bleedings and 1 (2%) perforation occurred, all managed endoscopically. Six (21%) bleedings (endoscopically managed), 4 (14%) cases of pancreatitis, and 1 (3%) perforation (conservatively treated) occurred after papillectomy. Duodenal surgery–free survival was 74% at 89 months after polypectomy and 71% at 71 months after papillectomy; no duodenal cancers were observed. After a median of 18 months (interquartile range, 10-40; range, 3-121) after polypectomy, Spigelman stages were significantly lower (P Conclusions In our FAP patients, prophylactic duodenal polypectomies were relatively safe. Papillectomies showed substantial adverse events, suggesting its benefits and risk should be carefully weighted. Both were effective, however, because surgical interventions were limited and none developed duodenal cancer.
- Published
- 2021
5. Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS®) pediatric item bank peer relationships in the Dutch general population
- Author
-
Raphaële R. L. van Litsenburg, Caroline B. Terwee, Martha A. Grootenhuis, Lotte Haverman, Michiel A. J. Luijten, Pediatric surgery, Epidemiology and Data Science, APH - Methodology, Graduate School, APH - Amsterdam Public Health, APH - Mental Health, Child and Adolescent Psychiatry & Psychosocial Care, and ARD - Amsterdam Reproduction and Development
- Subjects
Male ,Patient-Reported Outcomes Measurement Information System ,Psychometrics ,Adolescent ,Health-related quality of life ,Population ,Item bank ,Logistic regression ,01 natural sciences ,behavioral disciplines and activities ,Article ,Peer Group ,Validity ,010104 statistics & probability ,0504 sociology ,Quality of life ,Social functioning ,Humans ,Patient Reported Outcome Measures ,0101 mathematics ,education ,Child ,education.field_of_study ,05 social sciences ,Public Health, Environmental and Occupational Health ,Computerized adaptive testing ,050401 social sciences methods ,Reproducibility of Results ,Reliability ,Standard error ,Quality of Life ,Female ,Psychology ,Clinical psychology ,Information Systems - Abstract
Purpose This study aimed to validate the PROMIS Pediatric item bank v2.0 Peer Relationships and compare reliability of the full item bank to its short form, computerized adaptive test (CAT) and the social functioning (SF) subscale of the Pediatric Quality of Life Inventory (PedsQL™). Methods Children aged 8–18 (n = 1327), representative of the Dutch population completed the Peer Relationships item bank. A graded response model (GRM) was fit to the data. Structural validity was assessed by checking item-fit statistics (S-X2, p 0.50) was expected between Peer Relationships and the PedsQL SF subscale. Cross-cultural DIF between U.S. and NL was assessed using logistic regression, where an item with McFadden’s pseudo R2 > 0.02 was considered to have DIF. Percentage of participants reliably measured was assessed using the standard error of measurement (SEM) 2)/nitems) was calculated to compare how well the instruments performed relative to the amount of items administered. Results In total, 527 (response rate: 39.7%) children completed the PROMIS v2.0 Peer Relationships item bank (nitems = 15) and the PedsQL™ (nitems = 23). Structural validity of the Peer Relationships item bank was sufficient, but one item displayed misfit in the GRM model (S-X2 R2 = 0.0253). The item bank correlated moderately high (r = 0.61) with the PedsQL SF subscale Reliable measurements were obtained at the population mean and > 2SD in the clinically relevant direction. CAT outperformed all other measures in efficiency. Mean T-score of the Dutch general population was 46.9(SD 9.5). Conclusion The pediatric PROMIS Peer Relationships item bank was successfully validated for use within the Dutch population and reference data are now available.
- Published
- 2021
6. Usability and consistency in findings of the work support needs assessment tool
- Author
-
Monique H. W. Frings-Dresen, Saskia Andriessen, Karen Nieuwenhuijsen, Haije Wind, Maria J. E. Schouten, APH - Societal Participation & Health, Public and occupational health, APH - Mental Health, Coronel Institute of Occupational Health, APH - Amsterdam Public Health, APH - Quality of Care, and APH - Aging & Later Life
- Subjects
Disability ,business.industry ,Rehabilitation ,Applied psychology ,Work support ,education ,Public Health, Environmental and Occupational Health ,Usability ,Coaching ,Checklist ,Test (assessment) ,Consistency (negotiation) ,job coaching ,needs assessment ,Needs assessment ,employment ,vocational rehabilitation ,Humans ,Disabled Persons ,Duration (project management) ,business ,Psychology ,Research Article - Abstract
BACKGROUND: Structured work support needs assessment could facilitate professionals and increase assessment consistency. OBJECTIVES: Evaluating usability of the Work Support Needs Assessment Tool and test if professionals’ (labour experts, coaches) findings become more consistent after a tool training. The tool includes a 21 item checklist for assessing work support needs of people with disabilities. METHODS: Usability was explored through 28 interviews with professionals. Consistency was evaluated in an experimental pre-post study design, in which thirty-nine other professionals assessed work support needs of standardized clients before and after a protocolized training. Quantitative content analysis was conducted. Consistency of findings between professionals covered three categories: type (client-focused coaching), focus (topics to be addressed) and duration of support. An increase in consistency was defined as a decrease in the total number of different sub-categories of findings in each category. RESULTS: Nineteen professionals indicated that the tool was useful, as they gained relevant information and insights. Regarding consistency, the number of findings differed pre- and post-training for type of support (8 vs 9) and focus of support (18 vs 15 and 18 vs 17). CONCLUSIONS: Participants had positive experiences with the tool. Increased consistency in findings of professionals after the training was not demonstrated with the current study design.
- Published
- 2021
7. A potential for seamless designs in diagnostic research could be identified
- Author
-
Tim Friede, Patrick M.M. Bossuyt, Eric Bibiza, Werner Vach, Antonia Zapf, Oke Gerke, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, and APH - Amsterdam Public Health
- Subjects
Acceleration of research ,Comparative Effectiveness Research ,Blinding ,Epidemiology ,Computer science ,Process (engineering) ,Population ,Diagnostic accuracy ,03 medical and health sciences ,0302 clinical medicine ,Humans ,030212 general & internal medicine ,Change-in-management studies ,education ,Randomized Controlled Trials as Topic ,Protocol (science) ,education.field_of_study ,Diagnostic Tests, Routine ,Patient Selection ,Societal impact of nanotechnology ,Reference Standards ,Diagnostic studies ,Data Accuracy ,Variable (computer science) ,Treatment Outcome ,Risk analysis (engineering) ,Research Design ,Seamless designs ,Observational study ,Randomized diagnostic studies ,030217 neurology & neurosurgery ,Cut-point - Abstract
BACKGROUND AND OBJECTIVE: New diagnostic tests to identify a well-established disease state must undergo a series of scientific studies from test construction to finally demonstrating a societal impact. Traditionally, these studies are performed with substantial time gaps in between, resulting in a long time period from the initial idea to roll out in clinical practice including reimbursement. Seamless designs allowing us to combine a sequence of studies in one protocol may hence accelerate this process. Currently, a systematic investigation of the potential of seamless designs in diagnostic research is lacking.METHODS: We identify major study types in diagnostic research and their basic characteristics with respect to the application of seamless designs. This information is used to identify major hurdles and opportunities for seamless designs.RESULTS: The following major study types were identified: Variable construction studies, cut point finding studies, variable value studies, single-arm accuracy studies, comparative accuracy studies, change-in-management studies, observational discordant pair studies, randomized discordant pair studies, and randomized diagnostic studies. The following characteristics were identified: Type of recruitment (case-control vs. population-based), application of a reference standard, inclusion of a comparator, paired or unpaired application of a comparator, assessment of patient-relevant outcomes, and possibility for blinding of test results. Two basic hurdles could be identified: 1) Accuracy studies are hard to combine with postaccuracy studies in a seamless design for the following reasons. First, because the former are required to justify the latter and application of a reference test in outcome studies may be a threat to the integrity of the study. 2) Randomized diagnostic studies are probably best placed as singular studies at the end of the process, as all other questions should be clarified before performing such a study. However, otherwise there is a substantial potential for seamless designs. All steps from the construction to the comparison with the comparator can be combined in one protocol. This may include a switch from case-control to population-based recruitment as well as a switch from a single-arm study to a comparative accuracy study. In addition, change-in-management studies can be combined with an outcome study in discordant pairs.CONCLUSION: There is a potential for seamless designs in diagnostic research. It is wise to have the whole sequence of necessary studies in mind and to plan a full programme than rather individual studies one by one.
- Published
- 2021
8. Temporizing management vs immediate delivery in early-onset severe preeclampsia between 28 and 34 weeks of gestation (TOTEM study): An open-label randomized controlled trial
- Author
-
Joris van Drongelen, Caroline J. Bax, Hubertina C.J. Scheepers, Maureen T.M. Franssen, Johannes J. Duvekot, Eva van Horen, Ingrid A. Brussé, Peter H. Dijk, Kitty W. M. Bloemenkamp, Ruben G. Duijnhoven, Aleid G. van Wassenaer-Leemhuis, Arie Franx, Ben W.J. Mol, Martina Porath, Wessel Ganzevoort, Martijn A. Oudijk, Obstetrics and Gynaecology, AR&D - Amsterdam Reproduction & Development, Neonatology, Other Research, APH - Amsterdam Public Health, APH - Methodology, APH - Digital Health, APH - Quality of Care, RS: GROW - R4 - Reproductive and Perinatal Medicine, Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), Obstetrics & Gynecology, and Reproductive Origins of Adult Health and Disease (ROAHD)
- Subjects
Adult ,early-onset preeclampsia ,medicine.medical_specialty ,HELLP syndrome ,early‐onset preeclampsia ,Gestational Age ,EXPECTANT MANAGEMENT ,law.invention ,maternal morbidity ,preeclampsia ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Pre-Eclampsia ,law ,Interquartile range ,Medicine ,Humans ,030212 general & internal medicine ,Original Research Article ,Netherlands ,Pregnancy ,030219 obstetrics & reproductive medicine ,Placental abruption ,business.industry ,Obstetrics ,Pregnancy Outcome ,Obstetrics and Gynecology ,Gestational age ,General Medicine ,neonatal morbidity ,medicine.disease ,Delivery, Obstetric ,Intraventricular hemorrhage ,Bronchopulmonary dysplasia ,Female ,REMOTE ,pregnancy ,business ,temporizing management - Abstract
Introduction: There is little evidence to guide the timing of delivery of women with early-onset severe preeclampsia. We hypothesize that immediate delivery is not inferior for neonatal outcome but reduces maternal complications compared with temporizing management. Material and methods: This Dutch multicenter open-label randomized clinical trial investigated non-inferiority for neonatal outcome of temporizing management as compared with immediate delivery (TOTEM NTR 2986) in women between 27+5 and 33+5 weeks of gestation admitted for early-onset severe preeclampsia with or without HELLP syndrome. In participants allocated to receive immediate delivery, either induction of labor or cesarean section was initiated at least 48 hours after admission. Primary outcomes were adverse perinatal outcome, defined as a composite of severe respiratory distress syndrome, bronchopulmonary dysplasia, culture proven sepsis, intraventricular hemorrhage grade 3 or worse, periventricular leukomalacia grade 2 or worse, necrotizing enterocolitis stage 2 or worse, and perinatal death. Major maternal complications were secondary outcomes. It was estimated 1130 women needed to be enrolled. Analysis was by intention-to-treat. Results: The trial was halted after 35 months because of slow recruitment. Between February 2011 and December 2013, a total of 56 women were randomized to immediate delivery (n = 26) or temporizing management (n = 30). Median gestational age at randomization was 30 weeks. Median prolongation of pregnancy was 2 days (interquartile range 1-3 days) in the temporizing management group. Mean birthweight was 1435 g after immediate delivery vs 1294 g after temporizing management (P =.14). The adverse perinatal outcome rate was 55% in the immediate delivery group vs 52% in the temporizing management group (relative risk 1.06; 95% confidence interval 0.67-1.70). In both groups there was one neonatal death and no maternal deaths. In the temporizing treatment group, one woman experienced pulmonary edema and one placental abruption. Analyses of only the singleton pregnancies did not result in other outcomes. Conclusions: Early termination of the trial precluded any conclusions for the main outcomes. We observed that temporizing management resulted in a modest prolongation of pregnancy without changes in perinatal and maternal outcome. Conducting a randomized study for this important research question did not prove feasible.
- Published
- 2021
9. A nationwide database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy?
- Author
-
Willem A Bemelman, Geert R. D'Haens, Mark Löwenberg, S. van Dieren, Cyriel Y. Ponsioen, Christianne J. Buskens, Merel E. Stellingwerf, Graduate School, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Gastroenterology and Hepatology, APH - Amsterdam Public Health, and APH - Methodology
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,Colorectal cancer ,medicine.medical_treatment ,colorectal cancer ,Inflammatory bowel disease ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Appendectomy ,Colitis ,Aged ,Colectomy ,ulcerative colitis ,Aged, 80 and over ,business.industry ,Hazard ratio ,Nationwide database ,Middle Aged ,medicine.disease ,colectomy ,Ulcerative colitis ,digestive system diseases ,030220 oncology & carcinogenesis ,Colitis, Ulcerative ,Female ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,business - Abstract
Aim: Although has been suggested that an appendectomy has a positive effect on the disease course in patients with ulcerative colitis (UC), recent studies indicate a potential increase in risk of colectomy and colorectal cancer (CRC). This study aimed to evaluate the rates of colectomy and CRC after appendectomy in UC patients using a nationwide prospective database [the Initiative on Crohn and Colitis Parelsnoer Institute – Inflammatory Bowel Disease (ICC PSI-IBD) database]. Method: All UC patients were retrieved from the ICC PSI-IBD database between January 2007 and May 2018. Primary outcomes were colectomy and CRC. Outcomes were compared in patients with and without appendectomy, with a separate analysis for timing of appendectomy (before or after UC diagnosis). Results: A total of 826 UC patients (54.7% female; median age 46 years, range 18–89 years) were included. Sixty-three (7.6%) patients had previously undergone appendectomy: 24 (38.1%) before and 33 (52.4%) after their diagnosis of UC. In multivariate analysis, appendectomy after UC diagnosis was associated with a significantly lower colectomy rate compared with no appendectomy [hazard ratio (HR) 0.16, 95% C: 0.04–0.66, P = 0.011], and the same nonsignificant trend was seen in patients with an appendectomy before UC diagnosis (HR 0.35, 95% CI 0.08–1.41, P = 0.138). Appendectomy was associated with delayed colectomy, particularly when it was performed after diagnosis of UC (P = 0.009). No significant differences were found in the CRC rate between patients with and without appendectomy (1.6% vs 1.2%; P = 0.555). Conclusion: Appendectomy in established UC is associated with an 84% decreased risk of colectomy and a delay in surgery. Since the colon is in situ for longer, the risk of developing CRC remains, which underscores the importance of endoscopic surveillance programmes.
- Published
- 2021
10. The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study
- Author
-
Kim A.G.J. Romijnders, Laura de Groot, Sigrid C.J.M. Vervoort, Maartje G.J. Basten, Berend J. van Welzen, Mirjam E. Kretzschmar, Peter Reiss, Udi Davidovich, Ganna Rozhnova, Athena Institute, Sociale Psychologie (Psychologie, FMG), Psychology Other Research (FMG), Global Health, APH - Amsterdam Public Health, Internal Medicine, AII - Infectious diseases, and APH - Aging & Later Life
- Subjects
Quality of life ,History ,Polymers and Plastics ,Epidemiology ,HIV elimination ,Immunology ,HIV cure ,Public Health, Environmental and Occupational Health ,virus diseases ,HIV post-treatment control ,Sexual behaviour ,Industrial and Manufacturing Engineering ,Infectious Diseases ,SDG 3 - Good Health and Well-being ,Virology ,Qualitative research ,Business and International Management ,Sexual and gender minorities - Abstract
Introduction: When an HIV cure becomes available, it will have consequences for people living with HIV (PLHIV) and key populations who are vulnerable to HIV. This qualitative study aimed to explore the perceived impact of two HIV cure scenarios (post-treatment control when HIV is suppressed without the need for ongoing antiretroviral treatment (ART) and complete HIV elimination) on the quality of life of PLHIV and key populations living without HIV in the Netherlands.Methods: Participants were purposefully sampled from the Amsterdam Cohort Studies, the AGEhIV Cohort Study, the outpatient clinic of the University Medical Centre Utrecht and the Dutch HIV Association to increase variability. Semi-structured in-depth interviews were conducted between October 2020 and March 2021 and thematically analysed.Results: Of the 42 interviewed participants, 29 were PLHIV and 13 represented key populations (i.e., men who have sex with men and people injecting drugs). Both PLHIV and participants from vulnerable key populations hoped that a cure would result in normalization of their lives by removing the need to disclose HIV, reducing stigma and guilt, increasing independence of ART, and liberating sexual behaviour. Both groups believed only HIV elimination could accomplish this desired impact.Conclusions: While the post-treatment control scenario seems a more plausible outcome of current HIV cure research, our findings highlight that participants may not perceive it as a true cure. Involvement of PLHIV and vulnerable key populations in devising acceptable and feasible experimental approaches to HIV cure is essential to ensure their future successful implementation.
- Published
- 2022
11. Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study
- Author
-
Lotte M de Boer, Barbara A Hutten, Aeilko H Zwinderman, Albert Wiegman, Graduate School, Paediatric Metabolic Diseases, APH - Health Behaviors & Chronic Diseases, ACS - Diabetes & metabolism, APH - Aging & Later Life, Epidemiology and Data Science, ACS - Amsterdam Cardiovascular Sciences, APH - Methodology, APH - Amsterdam Public Health, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Heart failure & arrhythmias, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Lp(a) ,DNA analysis ,Cardiology and Cardiovascular Medicine ,Familial hypercholesterolaemia ,Children ,FH ,Lipoprotein(a) - Abstract
Aims Familial hypercholesterolaemia (FH) predisposes children to the early initiation of atherosclerosis and is preferably diagnosed by DNA analysis. Yet, in many children with a clinical presentation of FH, no mutation is found. Adult data show that high levels of lipoprotein(a) [Lp(a)] may underlie a clinical presentation of FH, as the cholesterol content of Lp(a) is included in conventional LDL cholesterol measurements. As this is limited to adult data, Lp(a) levels in children with and without (clinical) FH were evaluated. Methods and results Children were eligible if they visited the paediatric lipid clinic (1989–2020) and if Lp(a) measurement and DNA analysis were performed. In total, 2721 children (mean age: 10.3 years) were included and divided into four groups: 1931 children with definite FH (mutation detected), 290 unaffected siblings/normolipidaemic controls (mutation excluded), 108 children with probable FH (clinical presentation, mutation not detected), and 392 children with probable non-FH (no clinical presentation, mutation not excluded). In children with probable FH, 32% were found to have high Lp(a) [geometric mean (95% confidence interval) of 15.9 (12.3–20.6) mg/dL] compared with 10 and 10% [geometric means (95% confidence interval) of 11.5 (10.9–12.1) mg/dL and 9.8 (8.4–11.3) mg/dL] in children with definite FH (P = 0.017) and unaffected siblings (P = 0.002), respectively. Conclusion Lp(a) was significantly higher and more frequently elevated in children with probable FH compared with children with definite FH and unaffected siblings, suggesting that high Lp(a) may underlie the clinical presentation of FH when no FH-causing mutation is found. Performing both DNA analysis and measuring Lp(a) in all children suspected of FH is recommended to assess possible LDL cholesterol overestimation related to increased Lp(a).
- Published
- 2022
12. Distinct osmoregulatory responses to sodium loading in patients with altered glycosaminoglycan structure: a randomized cross-over trial
- Author
-
Liffert Vogt, Jetta J. Oppelaar, Arie Oosterhof, Rik H. G. Olde Engberink, Eliane F. E. Wenstedt, Stijn Besseling, Toin H. van Kuppevelt, Jan Aten, Bert-Jan H. van den Born, Nienke M. G. Rorije, Internal medicine, Pathology, ACS - Diabetes & metabolism, ACS - Atherosclerosis & ischemic syndromes, APH - Amsterdam Public Health, ACS - Amsterdam Cardiovascular Sciences, ACS - Microcirculation, Graduate School, Nephrology, Public and occupational health, Vascular Medicine, APH - Health Behaviors & Chronic Diseases, APH - Personalized Medicine, APH - Global Health, and ACS - Heart failure & arrhythmias
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Hereditary multiple exostoses ,Sodium ,lcsh:Medicine ,chemistry.chemical_element ,030204 cardiovascular system & hematology ,General Biochemistry, Genetics and Molecular Biology ,Dermatan sulfate ,Glycosaminoglycan ,03 medical and health sciences ,chemistry.chemical_compound ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Sulfation ,Osmoregulation ,Internal medicine ,medicine ,Humans ,Glycosaminoglycans ,Netherlands ,Cross-Over Studies ,Research ,lcsh:R ,General Medicine ,Heparan sulfate ,Crossover study ,Reconstructive and regenerative medicine Radboud Institute for Molecular Life Sciences [Radboudumc 10] ,030104 developmental biology ,Endocrinology ,Type 1 diabetes ,chemistry ,Nuclear factor of activated T-cells 5 ,Tonicity ,Heparitin Sulfate ,Homeostasis - Abstract
Background By binding to negatively charged polysaccharides called glycosaminoglycans, sodium can be stored in the body—particularly in the skin—without concurrent water retention. Concordantly, individuals with changed glycosaminoglycan structure (e.g. type 1 diabetes (DM1) and hereditary multiple exostosis (HME) patients) may have altered sodium and water homeostasis. Methods We investigated responses to acute (30-min infusion) and chronic (1-week diet) sodium loading in 8 DM1 patients and 7 HME patients in comparison to 12 healthy controls. Blood samples, urine samples, and skin biopsies were taken to investigate glycosaminoglycan sulfation patterns and both systemic and cellular osmoregulatory responses. Results Hypertonic sodium infusion increased plasma sodium in all groups, but more in DM1 patients than in controls. High sodium diet increased expression of nuclear factor of activated t-cells 5 (NFAT5)—a transcription factor responsive to changes in osmolarity—and moderately sulfated heparan sulfate in skin of healthy controls. In HME patients, skin dermatan sulfate, rather than heparan sulfate, increased in response to high sodium diet, while in DM1 patients, no changes were observed. Conclusion DM1 and HME patients show distinct osmoregulatory responses to sodium loading when comparing to controls with indications for reduced sodium storage capacity in DM1 patients, suggesting that intact glycosaminoglycan biosynthesis is important in sodium and water homeostasis. Trial registration These trials were registered with the Netherlands trial register with registration numbers: NTR4095 (https://www.trialregister.nl/trial/3933 at 2013-07-29) and NTR4788 (https://www.trialregister.nl/trial/4645 at 2014-09-12).
- Published
- 2021
13. Rare variants in KDR, encoding VEGF Receptor 2, are associated with tetralogy of Fallot
- Author
-
Doris Škorić-Milosavljević, Najim Lahrouchi, Fernanda M. Bosada, Gregor Dombrowsky, Simon G. Williams, Robert Lesurf, Fleur V.Y. Tjong, Roddy Walsh, Ihssane El Bouchikhi, Jeroen Breckpot, Enrique Audain, Aho Ilgun, Leander Beekman, Ilham Ratbi, Alanna Strong, Maximilian Muenke, Solveig Heide, Alison M. Muir, Mariam Hababa, Laura Cross, Dihong Zhou, Tomi Pastinen, Marc-Phillip Hitz, Hashim Abdul-Khaliq, Felix Berger, Ingo Dähnert, Sven Dittrich, Anselm Uebing, Brigitte Stiller, Elaine Zackai, Samir Atmani, Karim Ouldim, Najlae Adadi, Katharina Steindl, Anita Rauch, David Brook, Anna Wilsdon, Irene Kuipers, Nico A. Blom, Barbara J. Mulder, Heather C. Mefford, Boris Keren, Pascal Joset, Paul Kruszka, Isabelle Thiffault, Sarah E. Sheppard, Amy Roberts, Elisabeth M. Lodder, Bernard D. Keavney, Sally-Ann B. Clur, Seema Mital, Marc-Philip Hitz, Vincent M. Christoffels, Alex V. Postma, Connie R. Bezzina, Cardiology, ACS - Heart failure & arrhythmias, Medical Biology, ACS - Amsterdam Cardiovascular Sciences, Paediatric Cardiology, APH - Methodology, APH - Quality of Care, APH - Aging & Later Life, APH - Personalized Medicine, Human Genetics, APH - Amsterdam Public Health, ARD - Amsterdam Reproduction and Development, and ACS - Pulmonary hypertension & thrombosis
- Subjects
0301 basic medicine ,SIGNAL-TRANSDUCTION ,030204 cardiovascular system & hematology ,Biology ,Article ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Genetic variation ,medicine ,Missense mutation ,Genetics (clinical) ,Exome sequencing ,Tetralogy of Fallot ,Genetics ,Genetics & Heredity ,Science & Technology ,MUTATIONS ,HEK 293 cells ,Kinase insert domain receptor ,DEFECTS ,medicine.disease ,Human genetics ,CONGENITAL HEART-DISEASE ,030104 developmental biology ,VASCULOGENESIS ,cardiovascular system ,Life Sciences & Biomedicine - Abstract
PURPOSE: Rare genetic variants in KDR, encoding the vascular endothelial growth factor receptor 2 (VEGFR2), have been reported in patients with tetralogy of Fallot (TOF). However, their role in disease causality and pathogenesis remains unclear. METHODS: We conducted exome sequencing in a familial case of TOF and large-scale genetic studies, including burden testing, in >1,500 patients with TOF. We studied gene-targeted mice and conducted cell-based assays to explore the role of KDR genetic variation in the etiology of TOF. RESULTS: Exome sequencing in a family with two siblings affected by TOF revealed biallelic missense variants in KDR. Studies in knock-in mice and in HEK 293T cells identified embryonic lethality for one variant when occurring in the homozygous state, and a significantly reduced VEGFR2 phosphorylation for both variants. Rare variant burden analysis conducted in a set of 1,569 patients of European descent with TOF identified a 46-fold enrichment of protein-truncating variants (PTVs) in TOF cases compared to controls (P = 7 × 10-11). CONCLUSION: Rare KDR variants, in particular PTVs, strongly associate with TOF, likely in the setting of different inheritance patterns. Supported by genetic and in vivo and in vitro functional analysis, we propose loss-of-function of VEGFR2 as one of the mechanisms involved in the pathogenesis of TOF. ispartof: GENETICS IN MEDICINE vol:23 issue:10 pages:1952-1960 ispartof: location:United States status: published
- Published
- 2021
14. Interrogating the Impact of Intestinal Parasite-Microbiome on Pathogenesis of COVID-19 in Sub-Saharan Africa
- Author
-
Dawit Wolday, Geremew Tasew, Wondwossen Amogne, Britta Urban, Henk DFH Schallig, Vanessa Harris, Tobias F. Rinke de Wit, Medical Microbiology and Infection Prevention, AII - Amsterdam institute for Infection and Immunity, APH - Global Health, APH - Health Behaviors & Chronic Diseases, Global Health, APH - Amsterdam Public Health, Infectious diseases, AII - Infectious diseases, APH - Personalized Medicine, and APH - Quality of Care
- Subjects
Microbiology (medical) ,Opinion ,Intestinal parasite ,microbiome ,wa_395 ,Context (language use) ,parasites ,medicine.disease_cause ,Microbiology ,03 medical and health sciences ,protozoa ,Immune system ,parasitic diseases ,medicine ,Helminths ,Microbiome ,030304 developmental biology ,Schistosoma ,wa_105 ,helminths ,0303 health sciences ,biology ,030306 microbiology ,SARS-CoV-2 ,pathogenesis ,Human microbiome ,hyperinflammation ,COVID-19 ,medicine.disease ,biology.organism_classification ,Virology ,QR1-502 ,qx_20 ,Parasitic disease ,qz_40 ,qw_160 - Abstract
Intestinal parasitic infections affect more than 2 billion people throughout the world with disproportionately high prevalence rates in Low- and Middle-Income Countries (LMICs) (Herricks et al., 2017). Multicellular and highly complex parasites such as Ascaris, hook worm, Trichuris, Enterobius and Schistosoma, as well as unicellular organisms including Entamoeba, Giardia, Toxoplasma, Cyclospora, and Cryptosporidium are among major pathogens that contribute to the global intestinal parasitic disease burden.\ud \ud Parasites can cause persistent infection due to their ability to resist immune-mediated expulsion by modulating the host's immune response (McSorley and Maizels, 2012; Wammes et al., 2014; Chabé et al., 2017; Burrows et al., 2019; Ryan et al., 2020). There is a complex interaction between parasites and human microbiota which can triangulate with host's immune homeostasis and host responses to bystander antigens, vaccines or other unrelated diseases, both infectious and non-communicable diseases (McSorley and Maizels, 2012; Wammes et al., 2014). Recently, the world has grappled with an unprecedented pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) (WHO, 2020). The pathogenesis of severe disease in COVID-19 has been linked to the phenomenon of immune hyperactivation (Sinha et al., 2020; Tay et al., 2020). Here, we propose that the interplay between intestinal parasites and microbiome may have a potential direct or indirect effects on the pathogenesis of SARS-CoV-2 infection, in particular in the context of LMICs.
- Published
- 2021
- Full Text
- View/download PDF
15. Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathy
- Author
-
Gijs W. E. Santen, Damara Ortiz, Elisabeth M. Lodder, Francesca Clementina Radio, Michael V. Airola, Monique C. Haak, Dominic S Zimmerman, Quinn Gunst, Peter de Knijff, Katherine H. Kim, Viktor Stránecký, Stanislav Kmoch, Hiba Mustafa, Dmitriy Niyazov, H. Alex Brown, Najim Lahrouchi, Jamille Y. Robinson, Rick H. de Leeuw, Anne Sophie Denommé-Pichon, Sara Cherny, George A. Tanteles, Mariam Hababa, Joey V. Barnett, Doris Škorić-Milosavljević, Annemiek C. Dutman, Timothy J. Moss, Daniel M. de Laughter, Connie R. Bezzina, Zeev Perles, Fleur V.Y. Tjong, Matthew Ambrose, Forrest Z. Bowling, Arend D. J. ten Harkel, Katelijne Bouman, Barry Wolf, Monia Magliozzi, Asaf Ta-Shma, Lenka Piherová, Aho Ilgun, Sabrina C. Burn, Orly Elpeleg, Michael A. Frohman, Alex V. Postma, Maurice J.B. van den Hoff, Christian M. Salazar, Johanna C. Herkert, Christine Francannet, Jennifer Jacober, Andreas Rousounides, Leander Beekman, Barbara J.M. Mulder, Viktor Tomek, Bruel Ange-Line, Aphrodite Aristidou-Kallika, S. A. Clur, Gwendolyn T. R. Manten, Cardiology, ACS - Heart failure & arrhythmias, Human Genetics, Medical Biology, ACS - Pulmonary hypertension & thrombosis, ACS - Amsterdam Cardiovascular Sciences, ARD - Amsterdam Reproduction and Development, Graduate School, APH - Aging & Later Life, APH - Personalized Medicine, Paediatric Cardiology, and APH - Amsterdam Public Health
- Subjects
Heart Defects, Congenital ,Male ,0301 basic medicine ,Heart disease ,Heart Valve Diseases ,Cardiomyopathy ,HEART-DISEASE ,PHOSPHOLIPASE-D DEFINES ,03 medical and health sciences ,0302 clinical medicine ,DESIGN ,Loss of Function Mutation ,Phospholipase D ,Humans ,Medicine ,Missense mutation ,CRYSTAL-STRUCTURE ,Allele frequency ,Alleles ,Loss function ,Genetics ,business.industry ,GROWTH-FACTOR-BETA ,MUTATIONS ,INDUCTION ,FACTOR-ALPHA ,General Medicine ,medicine.disease ,Phenotype ,Ashkenazi jews ,TRANSFORMATION ,030104 developmental biology ,D1 ,030220 oncology & carcinogenesis ,Heart failure ,Female ,business ,Research Article - Abstract
Congenital heart disease is the most common type of birth defect, accounting for one-third of all congenital anomalies. Using whole-exome sequencing of 2718 patients with congenital heart disease and a search in GeneMatcher, we identified 30 patients from 21 unrelated families of different ancestries with biallelic phospholipase D1 (PLD1) variants who presented predominantly with congenital cardiac valve defects. We also associated recessive PLD1 variants with isolated neonatal cardiomyopathy. Furthermore, we established that p.1668F is a founder variant among Ashkenazi Jews (allele frequency of -.2%) and describe the phenotypic spectrum of PLD1-associated congenital heart defects. PLD1 missense variants were overrepresented in regions of the protein critical for catalytic activity, and, correspondingly, we observed a strong reduction in enzymatic activity for most of the mutant proteins in an enzymatic assay. Finally, we demonstrate that PLD1 inhibition decreased endothelial-mesenchymal transition, an established pivotal early step in valvulogenesis. In conclusion, our study provides a more detailed understanding of disease mechanisms and phenotypic expression associated with PLD1 loss of function.
- Published
- 2021
16. Chest CT in the emergency department for diagnosis of COVID-19 pneumonia
- Author
-
Mathias Prokop, Janette Rahamat-Langendoen, Daniel A. Korevaar, Henk Scheper, Tjalco van Rees Vellinga, Chantal P. Bleeker-Rovers, Loek P. Smits, Roos Wijnakker, Vanessa Harris, Frank J. Borm, Christine Korteweg, Steven Schalekamp, J. Lauran Stöger, Hester A. Gietema, Henriette M. E. Quarles van Ufford, Monique H. Reijers, Patricia M. Stassen, Anthonius S. M. Dofferhoff, Marieke Vermaat, Ludo F. M. Beenen, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Beeldvorming, MUMC+: DA BV Medisch Specialisten Radiologie (9), RS: CAPHRI - R5 - Optimising Patient Care, MUMC+: MA Alg Interne Geneeskunde (9), Interne Geneeskunde, Graduate School, Radiology and Nuclear Medicine, ACS - Microcirculation, ACS - Pulmonary hypertension & thrombosis, ANS - Neurovascular Disorders, APH - Global Health, APH - Health Behaviors & Chronic Diseases, Global Health, APH - Amsterdam Public Health, Infectious diseases, Pulmonology, ACS - Atherosclerosis & ischemic syndromes, ACS - Diabetes & metabolism, ANS - Brain Imaging, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, AMS - Amsterdam Movement Sciences, APH - Personalized Medicine, and APH - Methodology
- Subjects
rads ,SARS-CoV-2 = severe acute respiratory coronavirus 2 ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Subgroup analysis ,Sensitivity and Specificity ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Oxygen therapy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Reviews And Commentary ,Lung ,Aged ,Netherlands ,Retrospective Studies ,COVID-19 = coronavirus disease 2019 ,Receiver operating characteristic ,business.industry ,SARS-CoV-2 ,COVID-19 ,Retrospective cohort study ,Odds ratio ,Emergency department ,Middle Aged ,medicine.disease ,AUC = area under the receiver operating characteristic curve ,Pneumonia ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ,RT-PCR = reverse-transcription polymerase chain reaction ,Female ,Radiology ,business ,CO-RADS = COVID-19 Reporting and Data System ,Emergency Service, Hospital ,Tomography, X-Ray Computed ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
Background: Clinicians need to rapidly and reliably diagnose coronavirus disease 2019 (COVID-19) for proper risk stratification, isolation strategies, and treatment decisions.Purpose: To assess the real-life performance of radiologist emergency department chest CT interpretation for diagnosing COVID-19 during the acute phase of the pandemic, using the COVID-19 Reporting and Data System (CO-RADS).Materials and Methods: This retrospective multicenter study included consecutive patients who presented to emergency departments in six medical centers between March and April 2020 with moderate to severe upper respiratory symptoms suspicious for COVID-19. As part of clinical practice, chest CT scans were obtained for primary work-up and scored using the five-point CO-RADS scheme for suspicion of COVID-19. CT was compared with severe acute respiratory syndrome coronavirus 2 reverse-transcription polymerase chain reaction (RT-PCR) assay and a clinical reference standard established by a multidisciplinary group of clinicians based on RT-PCR, COVID-19 contact history, oxygen therapy, timing of RT-PCR testing, and likely alternative diagnosis. Performance of CT was estimated using area under the receiver operating characteristic curve (AUC) analysis and diagnostic odds ratios against both reference standards. Subgroup analysis was performed on the basis of symptom duration grouped presentations of less than 48 hours, 48 hours through 7 days, and more than 7 days.Results: A total of 1070 patients (median age, 66 years; interquartile range, 54-75 years; 626 men) were included, of whom 536 (50%) had a positive RT-PCR result and 137 (13%) of whom were considered to have a possible or probable COVID-19 diagnosis based on the clinical reference standard. Chest CT yielded an AUC of 0.87 (95% CI: 0.84, 0.89) compared with RT-PCR and 0.87(95% CI: 0.85, 0.89) compared with the clinical reference standard. A CO-RADS score of 4 or greater yielded an odds ratio of 25.9 (95% CI: 18.7, 35.9) for a COVID-19 diagnosis with RT-PCR and an odds ratio of 30.6 (95% CI: 21.1, 44.4) with the clinical reference standard. For symptom duration of less than 48 hours, the AUC fell to 0.71 (95% CI: 0.62, 0.80; P =.001).Conclusion: Chest CT analysis using the coronavirus disease 2019 (COVID-19) Reporting and Data System enables rapid and reliable diagnosis of COVID-19, particularly when symptom duration is greater than 48 hours. (C) RSNA, 2020
- Published
- 2021
17. Comparing video consultation and telephone consultation at the outpatient clinic of a tertiary referral centre: Patient and provider benefits
- Author
-
Anne Sophie H M van Dalen, Marlies P. Schijven, Pieter J. Tanis, Esther Z. Barsom, Christianne J. Buskens, Marjolein Blussé van Oud-Alblas, Willem A. Bemelman, Anthony W. H. van de Ven, Graduate School, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Other Research, Surgery, APH - Amsterdam Public Health, APH - Digital Health, and APH - Quality of Care
- Subjects
Modality (human–computer interaction) ,ComputingMilieux_THECOMPUTINGPROFESSION ,business.industry ,Tertiary referral centre ,Digital skills ,General Medicine ,medicine.disease ,Telephone consultation ,03 medical and health sciences ,surgical oncology ,0302 clinical medicine ,Patient satisfaction ,Video consultation ,030220 oncology & carcinogenesis ,gastrointestinal diseases ,Health care ,medicine ,Outpatient clinic ,030212 general & internal medicine ,Medical emergency ,business ,colorectal surgey ,ComputingMilieux_MISCELLANEOUS - Abstract
ObjectivesTelephone consultations are frequently used in the outpatient setting in order to avoid unnecessary travel and to reduce hospital visit-related costs for patients. However, they are limited by the absence of non-verbal communication in contrast to video consultation. Little is known considering the possible advantages of using video consultation in comparison to telephone consultation according to both patients and healthcare providers.MethodsPatients with colorectal diseases were asked to choose between a telephone consultation or a video consultation for their next appointment at the outpatient clinic of a tertiary referral centre. Willingness to use video consultation, value of non-verbal communication, patient satisfaction, provider satisfaction and user friendliness of the video connection technology were measured using questionnaires.ResultsNone of the included patients ever had a video consultation before with a healthcare provider. Nonetheless, 22/50 preferred a video consultation over a telephone consultation. Patients who preferred a video consultation underlined the benefits of providing visual feedback to both patients and healthcare providers. Moreover, healthcare providers felt they were better able to assess the patients’ healthcare condition.ConclusionFor patients who value both verbal and non-verbal interaction and feel comfortable with the use of video consultation, video consultation is the preferred contact modality. Shared decision making should be used to choose the preferred interaction modality. For patients with low digital skills, support might be needed or video consultation may not be the preferred choice.
- Published
- 2021
18. Germline variants in HEY2 functional domains lead to congenital heart defects and thoracic aortic aneurysms
- Author
-
Matthew E. Hurles, Danielle Posthuma, Anna Wilsdon, Alex V. Postma, Inge B. Mathijssen, Dianna M. Milewicz, Alessandra Maugeri, Quinten Waisfisz, Aho Ilgun, Jeanne E. Savage, Marc Philip Hitz, Iris E. Jansen, Enrique Audain Martinez, Frances A. Bu'Lock, Felix Berger, Vincent M. Christoffels, Ahmed S. Amin, Rob Zwart, Maša Umićević Mirkov, Gregor Dombrowsky, Hanne Meijers-Heijboer, Eva S. van Walree, Allard C. van der Wal, S. A. Clur, Sven Dittrich, Dongchuan Guo, Complex Trait Genetics, Amsterdam Neuroscience - Complex Trait Genetics, Oral Kinesiology, Human Genetics, ACS - Heart failure & arrhythmias, Medical Biology, ACS - Amsterdam Cardiovascular Sciences, Paediatric Cardiology, APH - Amsterdam Public Health, Cardiology, Pathology, ARD - Amsterdam Reproduction and Development, ACS - Pulmonary hypertension & thrombosis, Neurology, Amsterdam Neuroscience - Neurodegeneration, Pediatric surgery, Human genetics, ACS - Atherosclerosis & ischemic syndromes, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Heart Defects, Congenital ,thoracic aortic aneurysm ,Bioinformatics ,HEY2 ,Thoracic aortic aneurysm ,Article ,Germline ,congenital heart defect ,symbols.namesake ,SDG 3 - Good Health and Well-being ,medicine ,Basic Helix-Loop-Helix Transcription Factors ,Humans ,Genetic Predisposition to Disease ,Critical congenital heart disease ,Gene ,Exome ,Genetics (clinical) ,Sanger sequencing ,Aortic Aneurysm, Thoracic ,business.industry ,Heterozygote advantage ,medicine.disease ,Pedigree ,Repressor Proteins ,Germ Cells ,symbols ,cardiovascular defects ,business - Abstract
Purpose: In this study we aimed to establish the genetic cause of a myriad of cardiovascular defects prevalent in individuals from a genetically isolated population, who were found to share a common ancestor in 1728. Methods: Trio genome sequencing was carried out in an index patient with critical congenital heart disease (CHD); family members had either exome or Sanger sequencing. To confirm enrichment, we performed a gene-based association test and meta-analysis in two independent validation cohorts: one with 2685 CHD cases versus 4370. These controls were also ancestry-matched (same as FTAA controls), and the other with 326 cases with familial thoracic aortic aneurysms (FTAA) and dissections versus 570 ancestry-matched controls. Functional consequences of identified variants were evaluated using expression studies. Results: We identified a loss-of-function variant in the Notch target transcription factor-encoding gene HEY2. The homozygous state (n = 3) causes life-threatening congenital heart defects, while 80% of heterozygous carriers (n = 20) had cardiovascular defects, mainly CHD and FTAA of the ascending aorta. We confirm enrichment of rare risk variants in HEY2 functional domains after meta-analysis (MetaSKAT p = 0.018). Furthermore, we show that several identified variants lead to dysregulation of repression by HEY2. Conclusion: A homozygous germline loss-of-function variant in HEY2 leads to critical CHD. The majority of heterozygotes show a myriad of cardiovascular defects.
- Published
- 2022
19. EAES Recommendations for Recovery Plan in Minimally Invasive Surgery Amid COVID-19 Pandemic
- Author
-
Arezzo A., Francis N., Mintz Y., Adamina M., Antoniou S. A., Bouvy N., Copaescu C., de Manzini N., Di Lorenzo N., Morales-Conde S., Muller-Stich B. P., Nickel F., Popa D., Tait D., Thomas C., Nimmo S., Paraskevis D., Pietrabissa A., Eck M., Letic E., Preda S. D., Tsai A., Malanowska E., Lesko D., Majewski W., Baldari L., Morelli L., Shamiyeh A., Faria G., Carrano F. M., Mysliwiec P., Ahlberg G., Cassinotti E., Delibegovic S., Martinek L., Yiannakopoulou E., Gorter-Stam M., Hanna G., Fuchs H., Bjelovic M., Markar S., Yan P. W., Chiu, Ecom B. W., Kim Y. -W., Ponz C. B., Schijven M., Boni L., Carus T., Theodoropoulos G., Forgione A., Milone M., Petz W. L. R., Andrejevic P., Ignjatovic D., Arulampalam T., Campbell K., Chand M., Coleman M., Kontovounisios C., Sagiv C., Ficuciello F., Marconi S., Mascagni P., Nakajima K., Margallo F. M. S., Horeman T., Mylonas G., Valdastri P., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Heelkunde (9), Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, APH - Amsterdam Public Health, APH - Digital Health, APH - Quality of Care, Arezzo, A., Francis, N., Mintz, Y., Adamina, M., Antoniou, S. A., Bouvy, N., Copaescu, C., de Manzini, N., Di Lorenzo, N., Morales-Conde, S., Muller-Stich, B. P., Nickel, F., Popa, D., Tait, D., Thomas, C., Nimmo, S., Paraskevis, D., Pietrabissa, A., Eck, M., Letic, E., Preda, S. D., Tsai, A., Malanowska, E., Lesko, D., Majewski, W., Baldari, L., Morelli, L., Shamiyeh, A., Faria, G., Carrano, F. M., Mysliwiec, P., Ahlberg, G., Cassinotti, E., Delibegovic, S., Martinek, L., Yiannakopoulou, E., Gorter-Stam, M., Hanna, G., Fuchs, H., Bjelovic, M., Markar, S., Yan, P. W., Chiu, Ecom, B. W., Kim, Y. -W., Ponz, C. B., Schijven, M., Boni, L., Carus, T., Theodoropoulos, G., Forgione, A., Milone, M., Petz, W. L. R., Andrejevic, P., Ignjatovic, D., Arulampalam, T., Campbell, K., Chand, M., Coleman, M., Kontovounisios, C., Sagiv, C., Ficuciello, F., Marconi, S., Mascagni, P., Nakajima, K., Margallo, F. M. S., Horeman, T., Mylonas, G., and Valdastri, P.
- Subjects
medicine.medical_specialty ,Bariatrics ,Coronavirus disease 2019 (COVID-19) ,COVID-19 ,Delphi consensus ,EAES guidance ,Minimally invasive surgery ,Priority ,Delphi Technique ,Elective Surgical Procedures ,Emergencies ,Global Health ,Health Care Rationing ,Health Services Accessibility ,Humans ,Infection Control ,Minimally Invasive Surgical Procedures ,Pandemics ,SARS-CoV-2 ,media_common.quotation_subject ,Delphi method ,Plan (drawing) ,Voting ,Pandemic ,Global health ,Medicine ,computer.programming_language ,media_common ,Emergencie ,Medical education ,Science & Technology ,Delphi consensu ,Elective Surgical Procedure ,business.industry ,EAES Recommendations ,1103 Clinical Sciences ,Minimally Invasive Surgical Procedure ,Settore MED/18 ,Surgery ,EAES Group of Experts for Recovery Amid COVID-19 Pandemic ,business ,computer ,Life Sciences & Biomedicine ,Delphi ,Human - Abstract
Background COVID-19 pandemic presented an unexpected challenge for the surgical community in general and Minimally Invasive Surgery (MIS) specialists in particular. This document aims to summarize recent evidence and experts’ opinion and formulate recommendations to guide the surgical community on how to best organize the recovery plan for surgical activity across different sub-specialities after the COVID-19 pandemic. Methods Recommendations were developed through a Delphi process for establishment of expert consensus. Domain topics were formulated and subsequently subdivided into questions pertinent to different surgical specialities following the COVID-19 crisis. Sixty-five experts from 24 countries, representing the entire EAES board, were invited. Fifty clinicians and six engineers accepted the invitation and drafted statements based on specific key questions. Anonymous voting on the statements was performed until consensus was achieved, defined by at least 70% agreement. Results A total of 92 consensus statements were formulated with regard to safe resumption of surgery across eight domains, addressing general surgery, upper GI, lower GI, bariatrics, endocrine, HPB, abdominal wall and technology/research. The statements addressed elective and emergency services across all subspecialties with specific attention to the role of MIS during the recovery plan. Eighty-four of the statements were approved during the first round of Delphi voting (91.3%) and another 8 during the following round after substantial modification, resulting in a 100% consensus. Conclusion The recommendations formulated by the EAES board establish a framework for resumption of surgery following COVID-19 pandemic with particular focus on the role of MIS across surgical specialities. The statements have the potential for wide application in the clinical setting, education activities and research work across different healthcare systems.
- Published
- 2020
20. Fluorinated steroids do not improve outcome of isolated atrioventricular block
- Author
-
I.M. van Beynum, Ingrid M.E. Frohn-Mulder, Monique C. Haak, Martijn G. Slieker, Lukas A. J. Rammeloo, A. Reimer, Marry E.B. Rijlaarsdam, Caterina M. Bilardo, S. A. Clur, Gwendolyn T. R. Manten, N.W.E. Van Den Berg, Jérôme Cornette, Diederik R.H. de Bruijn, Matthias W. Freund, A.B.M.H. Rackowitz, K.E.H. van Loo-Maurus, Obstetrics and gynaecology, Pediatric surgery, ICaR - Heartfailure and pulmonary arterial hypertension, Reproductive Origins of Adult Health and Disease (ROAHD), Graduate School, Other departments, ACS - Amsterdam Cardiovascular Sciences, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Paediatric Cardiology, Kindergeneeskunde, MUMC+: MA Medische Staf Kindergeneeskunde (9), RS: FHML non-thematic output, and RS: CARIM School for Cardiovascular Diseases
- Subjects
Cardiomyopathy ,030204 cardiovascular system & hematology ,THERAPY ,DISEASE ,0302 clinical medicine ,Pregnancy ,Prenatal Diagnosis ,Prospective Studies ,Atrioventricular Block ,Netherlands ,Medicine(all) ,Dilated cardiomyopathy ,NEONATAL LUPUS ,DEXAMETHASONE ,Treatment Outcome ,In utero ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,ANTI-RO ,medicine.drug ,Adult ,medicine.medical_specialty ,Heart block ,IN-UTERO ,Congenital atrioventricular block ,Antibodies ,03 medical and health sciences ,Fetal Heart ,Internal medicine ,medicine ,Journal Article ,Humans ,Dexamethasone ,FETAL ,030203 arthritis & rheumatology ,Fetus ,CARDIOMYOPATHY ,business.industry ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,NATURAL-HISTORY ,medicine.disease ,CONGENITAL HEART-BLOCK ,business ,Atrioventricular block ,Anti-SSA/Ro autoantibodies ,Follow-Up Studies ,Steroids, Fluorinated - Abstract
Introduction: Congenital atrioventricular block (CAVB) is a rare disorder with a significant morbidity and mortality. Consensus regarding the prescription and efficacy of prenatal corticosteroids is lacking. This nationwide study was initiated to evaluate the effects of prenatal treatment with corticosteroids on the outcome of CAVB in The Netherlands.Methods: All fetuses identified with isolated congenital AVB-II degrees or AVB-III degrees in any of the eight academic fetal heart centers of The Netherlands between 2003 and 2013 were included and reviewed.Results: Fifty-six fetuses were included. Fourteen (25%) fetuses were treated with dexamethasone. We found no differences between the steroid-treated and untreated cases regarding in utero progression of the AVB (63% vs 67% respectively), survival to birth (86% vs 84%), pacemaker implantations (74% vs 58%) or long-term dilated cardiomyopathy (13% vs 17%). Steroid treated fetuses demonstrated more in utero growth restriction (38% vs 11%).Conclusion: No benefit from prenatal corticosteroid treatment was demonstrated for fetuses with isolated CAVB in this study. However, we found negative side effects. Our data provide no evidence to support the routine administration of corticosteroids for the treatment of fetal CAVB. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
- Published
- 2016
21. Prevalence, determinants and genetic diversity of hepatitis C virus in the multi-ethnic population living in Suriname
- Author
-
Stephen Vreden, Jimmy Roosblad, Richard Molenkamp, Maria Prins, Thijs J W van de Laar, Ashna D Hindori-Mohangoo, Jannie J. van der Helm, M. Sigrid Mac Donald-Ottevanger, John Codrington, Els Dams, Other departments, Medical Microbiology and Infection Prevention, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Infectious diseases
- Subjects
Adult ,Male ,medicine.medical_specialty ,Genotype ,Epidemiology ,Hepatitis C virus ,Population ,Ethnic group ,Hepacivirus ,Biology ,medicine.disease_cause ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Life ,Risk Factors ,Seroepidemiologic Studies ,CH - Child Health ,Virology ,Ethnicity ,Odds Ratio ,Prevalence ,medicine ,Humans ,030212 general & internal medicine ,Young adult ,education ,Phylogeny ,Aged ,education.field_of_study ,Suriname ,Genetic Variation ,virus diseases ,Hepatitis C ,Odds ratio ,Middle Aged ,medicine.disease ,digestive system diseases ,Health ,Female ,030211 gastroenterology & hepatology ,ELSS - Earth, Life and Social Sciences ,Healthy for Life ,Healthy Living ,Demography - Abstract
Little is known about the epidemiology of HCV in Suriname, a former Dutch colony in South America. To study the prevalence, determinants and genetic diversity of HCV, a one-month survey was conducted at the only Emergency Department in the capital Paramaribo. Participants (>= 18 years) completed an interviewer-led standardized HCV risk-factor questionnaire, were tested for HCV-antibodies, and if positive also for HCV RNA. The overall HCV prevalence was 1.0% (22/2128 participants; 95%CI 0.7-1.5). Male sex (OR=4.11; 95%CI 1.30-13.01), older age (OR=1.06 per year increase; 95%CI 1.04-1.09), Javanese ethnicity (OR=7.84; 95%CI 3.25-18.89) and cosmetic tattooing (OR=31.7; 95%CI 3.25-323.87) were independently associated with HCV-infection. Phylogenetic analysis revealed six distinct HCV subtypes, all HCV-geno-type 2 (HCV-2): subtype 2f (also circulating in Indonesia) plus five yet unassigned HCV-2 subtypes exclusively linked to Suriname. (C) 2016 Elsevier Inc. All rights reserved
- Published
- 2016
22. Gender inequality and the double burden of disease in low-income and middle-income countries: an ecological study
- Author
-
Mirte van der Ham, Alcira de Vries, Maiza Campos Ponce, Renee Bolijn, Irene G. M. van Valkengoed, APH - Health Behaviors & Chronic Diseases, APH - Global Health, Graduate School, APH - Amsterdam Public Health, Public and occupational health, ACS - Diabetes & metabolism, APH - Methodology, and Infectious Diseases
- Subjects
Male ,medicine.medical_specialty ,Double burden ,Disease ,Logistic regression ,social medicine ,03 medical and health sciences ,0302 clinical medicine ,Cost of Illness ,Social medicine ,Epidemiology ,Humans ,Medicine ,030212 general & internal medicine ,Noncommunicable Diseases ,Developing Countries ,Poverty ,030505 public health ,business.industry ,Public health ,public health ,Gender Inequality Index ,Ecological study ,General Medicine ,SDG 11 - Sustainable Cities and Communities ,Socioeconomic Factors ,Income ,Female ,epidemiology ,0305 other medical science ,business ,Demography - Abstract
IntroductionMany low-income and middle-income countries (LMIC) suffer from a double burden of infectious diseases (ID) and non-communicable diseases (NCD). Previous research suggests that a high rate of gender inequality is associated with a higher ID and NCD burden in LMIC, but it is unknown whether gender inequality is also associated with a double burden of disease. In this ecological study, we explored the association between gender inequality and the double burden of disease in LMIC.MethodsFor 108 LMIC, we retrieved the Gender Inequality Index (GII, scale 0–1) and calculated the double burden of disease, based on disability-adjusted life-years for a selection of relevant ID and NCD, using WHO data. We performed logistic regression analysis to study the association between gender inequality and the double burden of disease for the total population, and stratified for men and women. We adjusted for income, political stability, type of labour, urbanisation, government health expenditure, health infrastructure and unemployment. Additionally, we conducted linear regression models for the ID and NCD separately.ResultsThe GII ranged from 0.13 to 0.83. A total of 37 LMIC had a double burden of disease. Overall, the adjusted OR for double burden of disease was 1.05 per 0.01 increase of GII (95% CI 0.99 to 1.10, p=0.10). For women, there was a borderline significant positive association between gender inequality and double burden of disease (OR 1.05, 95% CI 1.00 to 1.11, p=0.06), while there was no association in men (OR 0.99, 95% CI 0.95 to 1.04, p=0.75).ConclusionWe found patterns directing towards a positive association between gender inequality and double burden of disease, overall and in women. This finding suggests the need for more attention for structural factors underlying gender inequality to potentially reduce the double burden of disease.
- Published
- 2021
23. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding
- Author
-
Jan Willem van der Steeg, Diana S. Massop-Helmink, Lucet F. van der Voet, Patrick M. M. Bossuyt, Heleen P. Eising, Pleun Beelen, Theodoor E. Nieboer, Janny H. Dekker, Sjors F.P.J. Coppus, Ruben G. Duijnhoven, Marlies Y. Bongers, Ellen R. Klinkert, Marjolein Y. Berger, Marian J van den Brink, Anne Timmermans, Joke M. Schutte, Nienke Mak, Nicol A. C. Smeets, Peggy M.A.J. Geomini, Sebastiaan Veersema, Malou C. Herman, Marchien van Baal, Ben W.J. Mol, Hannah S. van Meurs, Obstetrics and Gynaecology, APH - Amsterdam Public Health, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, APH - Aging & Later Life, RS: GROW - R4 - Reproductive and Perinatal Medicine, Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), Life Course Epidemiology (LCE), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Subjects
medicine.medical_treatment ,0302 clinical medicine ,Obstetrics and gynaecology ,Quality of life ,Levonorgestrel ,030212 general & internal medicine ,IUS ,SCALE ,Netherlands ,030219 obstetrics & reproductive medicine ,Obstetrics ,Intrauterine Devices, Medicated ,Obstetrics and Gynecology ,WOMEN ,General Medicine ,Middle Aged ,intrauterine device ,Treatment Outcome ,Contraceptive Agents, Hormonal ,Patient Satisfaction ,Retreatment ,Endometrial ablation ,THERMAL BALLOON ABLATION ,Female ,TRIAL ,5-YEAR FOLLOW-UP ,Sexual Health ,medicine.drug ,Adult ,medicine.medical_specialty ,RESECTION ,Intrauterine device ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Patient satisfaction ,Mirena ,menorrhagia ,medicine ,Humans ,Endometrial Ablation Techniques ,Pregnancy ,business.industry ,excessive uterine bleeding ,medicine.disease ,NovaSure ,Menstrual bleeding ,Increased risk ,Quality of Life ,business ,Sexual function - Abstract
Heavy menstrual bleeding (HMB) can negatively influence physical activity, work productivity, and sexual life and therefore has a major impact on women's quality of life (QoL). The National Institute for Health and Care Excellence guidelines recommend the levonorgestrel-releasing intrauterine system (LNG-IUS) as the treatment of first choice for HMB. Surgical treatments for treating HMB in women without future pregnancy wish include endometrial ablation (EA) and hysterectomy. Because of potentially biased studies and conflicting results on bleeding scores, satisfaction, and reintervention rate, there is no consensus on the efficacy of LNG-IUS versus EA. This multicenter, randomized controlled, noninferiority trial aimed to compare the effectiveness of the LNG-IUS system with EA in women with HMB. This study was performed between 2012 and 2016 in 26 hospitals in the Netherlands. Women were considered eligible if they had a diagnosed HMB with a Pictorial Blood Loss Assessment Chart (PBAC) score exceeding 150 points, were older than 34 years, had no pregnancy wish, and had no abnormal cervix cytology in the past 5 years. Participants were randomized in a 1:1 ratio to either the LNG-IUS or EA cohort. The LNG-IUS cohort had implantation of the device containing a total of 52 mg of levonorgestrel, releasing 20 μg/d. The EA intervention was performed with a bipolar radiofrequency device either in the office under local anesthetics or in the operating room under general or spinal anesthesia. The primary study outcome was menstrual blood loss at 24 months after randomization in PBAC, measured by participants through standardized questionnaires. Participants completed questionnaires before treatment and at 3, 6, 12, and 24 months after randomization. The primary analysis was an intention-to-treat analysis with a hypothesis that LNG-IUS would be noninferior to EA. Noninferiority of the LNG-IUS protocol would be established if the upper limit of the 95% confidence interval (CI) for the difference in PBAC score did not exceed the predetermined noninferiority margin of 25 points with P < 0.05. A total of 270 participants were randomized to initial treatment with LNG-IUS (n = 132) or treatment with EA (n = 138) between April 2012 and January 2016. A total of 247 participants (91%) reported PBAC scores at 24 months. The mean PBAC score was 64.8 in the LNG-IUS group compared with 14.2 in the EA group (mean difference, 50.5; 95% CI, 4.3-96.7). Noninferiority of LNG-IUS could not be demonstrated (noninferiority, P = 0.87). At 3 months of follow-up, 60% of women in the LNG-IUS group had reached a PBAC score of less than 75 points compared with 83% of women in the EA group (relative risk, 0.72; 95% CI, 0.59-0.87). The LNG-IUS was removed in 49 women (39%), and those in the LNG-IUS cohort were more likely to receive a surgical or drug reintervention within 24 months compared with women in the EA group (35% vs 20%; relative risk, 1.77; 95% CI, 1.17-2.68). There was no statistically significant difference in participant satisfaction and QoL between the cohorts. This study found that both the LNG-IUS and EA protocols for HMB led to a large decrease in menstrual blood loss, with LNG-IUS resulting in an increased risk of needing additional treatment and EA achieving a greater decrease in blood loss, with comparable QoL and satisfaction scores. Noninferiority of LNG-IUS compared with EA could not be demonstrated.
- Published
- 2021
24. Return to work following acquired brain injury: the views of patients and employers
- Author
-
Haije Wind, Maria J. E. Schouten, Birgit H. P. M. Donker-Cools, Monique H. W. Frings-Dresen, APH - Amsterdam Public Health, Coronel Institute of Occupational Health, APH - Societal Participation & Health, and Other departments
- Subjects
Adult ,Male ,030506 rehabilitation ,medicine.medical_specialty ,Attitude of Health Personnel ,Traumatic brain injury ,Return to work ,03 medical and health sciences ,Return to Work ,0302 clinical medicine ,medicine ,Humans ,Workplace ,Stroke ,Acquired brain injury ,Qualitative Research ,Netherlands ,business.industry ,Rehabilitation ,Middle Aged ,medicine.disease ,Sensory overload ,Social Perception ,Brain Injuries ,Physical therapy ,Female ,0305 other medical science ,business ,Attitude to Health ,Needs Assessment ,030217 neurology & neurosurgery ,Qualitative research - Abstract
To investigate which factors are experienced as facilitators of or barriers to return to work (RTW), or as solutions to RTW-problems, by patients with acquired brain injury (ABI) and by employers.Qualitative study.Ten patients with ABI and seven employers participated in semi-structured interviews. Patients and employers were unrelated. Transcripts were open coded. Factors perceived to be facilitators, barriers, or solutions to RTW-problems were grouped on a thematic basis.Both patients and employers distinguished patient-related and work-related facilitators. When questioned about barriers, both patients and employers emphasized the importance of work-related factors such as sensory overload at the workplace and condition-related factors such as fatigue. Patients regarded poor guidance and support as barriers, but employers did not. Employers and patients suggested that solutions to RTW-problems were work-related, if necessary backed up by professional supervision. Patients also mentioned the need for understanding and acceptance of the limitations resulting from ABI.Both patients and employers mentioned work-related and patient-related facilitators, work-related and condition-related barriers, and work-related solutions to RTW-problems. Patients mentioned lack of guidance and support as barriers, and stressed the need for understanding and acceptance of the limitations resulting from ABI in any RTW-solution. Implications for rehabilitation •Patients and employers are important stakeholders in the return to work (RTW) process of a patient with acquired brain injury (ABI) •Professionals in rehabilitation practice, occupational and insurance physicians need to help patients and employers to realize RTW •Professionals have to be aware of the perspectives of patients and employers regarding RTW, such as: ^Little understanding of limitations resulting from ABI ^Work-related aspects hindering RTW, such as sensory overload and high work pressure ^Condition-related barriers to RTW such as (invisible) cognitive limitations and fatigue ^Need for professional assistance during the RTW process.
- Published
- 2016
25. Cost-utility of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of FALLs (IMPROveFALL) trial
- Author
-
Suzanne Polinder, Nicole D. A. Boyé, Francesco U. S. Mattace-Raso, Nathalie Van der Velde, Klaas A. Hartholt, Oscar J. De Vries, Paul Lips, Tischa J. M. Van der Cammen, Peter Patka, Ed F. Van Beeck, Esther M. M. Van Lieshout, the IMPROveFALL trial collaborators, Public Health, Internal Medicine, Surgery, Emergency Medicine, APH - Amsterdam Public Health, AMS - Amsterdam Movement Sciences, Geriatrics, Internal medicine, and EMGO - Musculoskeletal health
- Subjects
Male ,Quality of life ,medicine.medical_specialty ,Aging ,Prescription Drugs ,medicine.medical_treatment ,Medication withdrawal ,Cost utility ,lcsh:Geriatrics ,Risk Assessment ,law.invention ,03 medical and health sciences ,Indirect costs ,0302 clinical medicine ,McNemar's test ,Randomized controlled trial ,law ,Intervention (counseling) ,Health care ,medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Geriatric Assessment ,Aged ,Netherlands ,Aged, 80 and over ,Rehabilitation ,business.industry ,Emergency department ,lcsh:RC952-954.6 ,Outcome and Process Assessment, Health Care ,Withholding Treatment ,Older persons ,Physical therapy ,Accidental Falls ,Female ,Falls ,Geriatrics and Gerontology ,business ,Emergency Service, Hospital ,030217 neurology & neurosurgery ,Research Article - Abstract
Background The use of Fall-Risk-Increasing-Drugs (FRIDs) has been associated with increased risk of falls and associated injuries. This study investigates the effect of withdrawal of FRIDs versus ‘care as usual’ on health-related quality of life (HRQoL), costs, and cost-utility in community-dwelling older fallers. Methods In a prospective multicenter randomized controlled trial FRIDs assessment combined with FRIDs-withdrawal or modification was compared with ‘care as usual’ in older persons, who visited the emergency department after experiencing a fall. For the calculation of costs the direct medical costs (intramural and extramural) and indirect costs (travel costs) were collected for a 12 month period. HRQoL was measured at baseline and at 12 months follow-up using the EuroQol-5D and Short Form-12 version 2. The change in EuroQol-5D and Short Form-12 scores over 12 months follow-up within the control and intervention groups was compared using the Wilcoxon Signed Rank test for continuous variables and the McNemar test for dichotomous variables. The change in scores between the control and intervention groups were compared using a two-way analysis of variance. Results We included 612 older persons who visited an emergency department because of a fall. The mean cost of the FRIDs intervention was €120 per patient. The total fall-related healthcare costs (without the intervention costs) did not differ significantly between the intervention group and the control group (€2204 versus €2285). However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant. Furthermore, the control group had a greater decline in EuroQol-5D utility score during the 12-months follow-up than the intervention group (p = 0.02). The change in the Short Form-12 Physical Component Summary and Mental Component Summary scores did not differ significantly between the two groups. Conclusions Withdrawal of FRID’s in older persons who visited an emergency department due to a fall, did not lead to reduction of total health-care costs. However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant in combination with less decline in HRQoL is an important result. Trial registration The trial is registered in the Netherlands Trial Register (NTR1593 – October 1st 2008). Electronic supplementary material The online version of this article (doi:10.1186/s12877-016-0354-7) contains supplementary material, which is available to authorized users.
- Published
- 2016
26. Can the composition of the intestinal microbiota predict the development of urinary tract infections?
- Author
-
Mariëlle A. J. Beerepoot, John Penders, Jan M. Prins, Ellen E. Stobberingh, Casper D. J. den Heijer, Suzanne E. Geerlings, Promovendi PHPC, MUMC+: DA MMI Toegelatenen (9), Medische Microbiologie, RS: CAPHRI - R4 - Health Inequities and Societal Participation, RS: NUTRIM - R2 - Gut-liver homeostasis, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Infectious diseases, and Oncology
- Subjects
DNA, Bacterial ,0301 basic medicine ,Microbiology (medical) ,intestinal microbiota ,lactobacilli ,Time Factors ,Urinary system ,Microbial diversity ,Physiology ,postmenopausal women ,Biology ,urologic and male genital diseases ,Microbiology ,trimethoprim-sulfamethoxazole ,Feces ,03 medical and health sciences ,0302 clinical medicine ,fluids and secretions ,RNA, Ribosomal, 16S ,Trimethoprim, Sulfamethoxazole Drug Combination ,Humans ,030212 general & internal medicine ,16S rRNA pyrosequencing ,Phylogeny ,Microbiological Phenomena ,Postmenopausal women ,Probiotics ,Microbial composition ,Biodiversity ,Antibiotic Prophylaxis ,Middle Aged ,Fecal microbiota ,bacterial infections and mycoses ,female genital diseases and pregnancy complications ,Gastrointestinal Microbiome ,Postmenopause ,Lactobacillus ,030104 developmental biology ,Urinary Tract Infections ,Immunology ,Pyrosequencing ,Female ,prophylaxis ,urinary tract infection - Abstract
Aim: To evaluate whether intestinal microbiota predicts the development of new-onset urinary tract infections (UTIs) in postmenopausal women with prior recurrent UTIs (rUTIs). Patients & methods: Fecal samples (n = 40) originated from women with rUTI who received 12 months’ prophylaxis of either trimethoprim–sulfamethoxazole (TMP–SMX) or lactobacilli. Microbial composition was assessed by 16S rRNA pyrosequencing. Results: At baseline, fecal microbiota of women with zero and more than or equal to four UTIs during follow-up showed no significant differences. Only TMP–SMX prophylaxis resulted in reduced microbial diversity. Microbial structure of two samples from the same woman showed limited relatedness. Conclusion: In postmenopausal women with rUTI, the intestinal microbiota was not predictive for new-onset UTIs. Only TMP–SMX, and not lactobacilli, prophylaxis had effects on the microbial composition. Data in ENA:PRJEB13868.
- Published
- 2016
27. Influence of embryo culture medium (G5 and HTF) on pregnancy and perinatal outcome after IVF
- Author
-
Luc J.M. Smits, Alex M.M. Wetzels, John C.M. Dumoulin, Dimitri Consten, Sjoerd Repping, Eleni Mantikou, Jannie van Echten-Arends, Sebastiaan Mastenbroek, Aafke P.A. van Montfoort, Els Slappendel, Madelon van Wely, Sander H.M. Kleijkers, Other departments, APH - Amsterdam Public Health, ARD - Amsterdam Reproduction and Development, Center for Reproductive Medicine, General Paediatrics, Promovendi ODB, Obstetrie & Gynaecologie, Epidemiologie, RS: CAPHRI - R5 - Optimising Patient Care, RS: GROW - R4 - Reproductive and Perinatal Medicine, and MUMC+: VMK IVF Lab (9)
- Subjects
Male ,0301 basic medicine ,law.invention ,Embryo Culture Techniques ,0302 clinical medicine ,Randomized controlled trial ,Pregnancy ,law ,Birth Weight ,AMINO-ACIDS ,GENE-EXPRESSION ,030219 obstetrics & reproductive medicine ,Obstetrics ,Rehabilitation ,Pregnancy Outcome ,Obstetrics and Gynecology ,Gestational age ,NEONATAL BIRTH-WEIGHT ,ASSISTED REPRODUCTION TECHNOLOGY ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,SEQUENTIAL MEDIA ,birthweight ,IVF ,Female ,Live birth ,medicine.medical_specialty ,Randomization ,culture medium ,DATING FORMULAS ,Offspring ,Birth weight ,Fertilization in Vitro ,ICSI ,live birth ,03 medical and health sciences ,Double-Blind Method ,medicine ,Humans ,Gynecology ,business.industry ,Infant, Newborn ,IN-VITRO CULTURE ,Embryo culture ,medicine.disease ,Culture Media ,030104 developmental biology ,Reproductive Medicine ,HUMAN PREIMPLANTATION EMBRYOS ,PROTEIN SUPPLEMENTS ,business ,CHILDREN BORN - Abstract
Item does not contain fulltext STUDY QUESTION: Does embryo culture medium influence pregnancy and perinatal outcome in IVF? SUMMARY ANSWER: Embryo culture media used in IVF affect treatment efficacy and the birthweight of newborns. WHAT IS KNOWN ALREADY: A wide variety of culture media for human preimplantation embryos in IVF/ICSI treatments currently exists. It is unknown which medium is best in terms of clinical outcomes. Furthermore, it has been suggested that the culture medium used for the in vitro culture of embryos affects birthweight, but this has never been demonstrated by large randomized trials. STUDY DESIGN, SIZE, DURATION: We conducted a multicenter, double-blind RCT comparing the use of HTF and G5 embryo culture media in IVF. Between July 2010 and May 2012, 836 couples (419 in the HTF group and 417 in the G5 group) were included. The allocated medium (1:1 allocation) was used in all treatment cycles a couple received within 1 year after randomization, including possible transfers with frozen-thawed embryos. The primary outcome was live birth rate. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples that were scheduled for an IVF or an ICSI treatment at one of the six participating centers in the Netherlands or their affiliated clinics. MAIN RESULTS AND THE ROLE OF CHANCE: The live birth rate was higher, albeit nonsignificantly, in couples assigned to G5 than in couples assigned to HTF (44.1% (184/417) versus 37.9% (159/419); RR: 1.2; 95% confidence interval (CI): 0.99-1.37; P = 0.08). Number of utilizable embryos per cycle (2.8 +/- 2.3 versus 2.3 +/- 1.8; P < 0.001), implantation rate after fresh embryo transfer (20.2 versus 15.3%; P < 0.001) and clinical pregnancy rate (47.7 versus 40.1%; RR: 1.2; 95% CI: 1.02-1.39; P = 0.03) were significantly higher for couples assigned to G5 compared with those assigned to HTF. Of the 383 live born children in this trial, birthweight data from 380 children (300 singletons (G5: 163, HTF: 137) and 80 twin children (G5: 38, HTF: 42)) were retrieved. Birthweight was significantly lower in the G5 group compared with the HTF group, with a mean difference of 158 g (95% CI: 42-275 g; P = 0.008). More singletons were born preterm in the G5 group (8.6% (14/163) versus 2.2% (3/137), but singleton birthweight adjusted for gestational age and gender (z-score) was also lower in the G5 than in the HTF group (-0.13 +/- 0.08 versus 0.17 +/- 0.08; P = 0.008). LIMITATIONS, REASONS FOR CAUTION: This study was powered to detect a 10% difference in live births while a smaller difference could still be clinically relevant. The effect of other culture media on perinatal outcome remains to be determined. WIDER IMPLICATIONS OF THE FINDINGS: Embryo culture media used in IVF affect not only treatment efficacy but also perinatal outcome. This suggests that the millions of human embryos that are cultured in vitro each year are sensitive to their environment. These findings should lead to increased awareness, mechanistic studies and legislative adaptations to protect IVF offspring during the first few days of their existence. STUDY FUNDING/COMPETING INTERESTS: This project was partly funded by The NutsOhra foundation (Grant 1203-061) and March of Dimes (Grant 6-FY13-153). The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: NTR1979 (Netherlands Trial Registry). TRIAL REGISTRATION DATE: 1 September 2009. DATE OF FIRST PATIENT'S ENROLMENT: 18 July 2010.
- Published
- 2016
28. Prevalence, diagnosis and outcome of cleft lip with or without cleft palate in The Netherlands
- Author
-
J. H. Fleurke-Rozema, R. J. M. Snijders, Marian K. Bakker, K. van de Kamp, Caterina M. Bilardo, Eva Pajkrt, Reproductive Origins of Adult Health and Disease (ROAHD), Obstetrics and gynaecology, Graduate School, APH - Amsterdam Public Health, ARD - Amsterdam Reproduction and Development, Obstetrics and Gynaecology, and Other departments
- Subjects
Adult ,medicine.medical_specialty ,Pediatrics ,Adolescent ,IMPACT ,ACCURACY ,Population ,anomaly scan ,cleft lip ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,registration ,Prenatal Diagnosis ,Prevalence ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,education ,POPULATION ,Netherlands ,Comparative Genomic Hybridization ,education.field_of_study ,Pregnancy ,Fetus ,030219 obstetrics & reproductive medicine ,Radiological and Ultrasound Technology ,business.industry ,Obstetrics ,screening ,Facial cleft ,OROFACIAL CLEFTS ,Obstetrics and Gynecology ,FACIAL CLEFTS ,General Medicine ,medicine.disease ,PRENATAL ULTRASOUND ,Cleft Palate ,facial cleft ,PREGNANCY ,Reproductive Medicine ,Gestation ,Female ,Birth records ,business ,Healthcare providers ,SCAN ,Fetal medicine - Abstract
Objective To examine the accuracy and timing of diagnosis of fetal cleft lip with or without cleft palate (CL +/- P) in the years following the introduction of a national screening program, and to assess the completeness and accuracy of information in The Netherlands Perinatal Registry.Methods A list was obtained of cases with a prenatal or postnatal diagnosis of CL +/- P from two fetal medicine units between 2008 and 2012. All cases of CL +/- P were included irrespective of the presence or absence of additional anomalies. Cases were included if the estimated date of delivery was between 1 January 2008 and 31 December 2012.Results During the study period, 330 cases of CL +/- P were identified, with a prevalence of 15 per 10 000 pregnancies. The number of cases that were detected before 24 weeks' gestation increased during the study period, while the rate of termination of pregnancy did not change significantly (P=0.511). CL +/- P was isolated in 217 (66%) cases and karyotype was abnormal in 69 (21%) cases. In 5% of the cases in which CL +/- P seemed to be isolated during the 18-23-week anomaly scan, postnatal array comparative genomic hybridization (array-CGH) revealed an abnormal karyotype and 50% of these cases had major additional anomalies. Examination of data from The Netherlands Perinatal Registry demonstrated that in 37% of cases CL +/- P was not recorded in the pregnancy records.Conclusion CL +/- P is increasingly being diagnosed prenatally, without a significant effect on the rate of pregnancy termination. Further improvement in the diagnostic accuracy may be achieved by advocating prenatal array-CGH to reduce the frequency of unexpected anomalies being diagnosed after birth. It is important that healthcare providers register accurately the presence or absence of anomalies in the birth records to ensure that, in the future, data from The Netherlands Perinatal Registry can be relied upon to monitor prevalence. Copyright (C) 2015 ISUOG. Published by John Wiley & Sons Ltd.
- Published
- 2016
29. Four-Year Follow-up of Cognitive Behavioral Therapy in Persons at Ultra-High Risk for Developing Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial
- Author
-
Sara Dragt, Judith Rietdijk, Dorien H. Nieman, Nynke Boonstra, Don H. Linszen, Filip Smit, Lex Wunderink, Mark van der Gaag, David Van Den Berg, Tamar Kraan, Rianne M. C. Klaassen, Monique Willebrands-Mendrik, Helga K. Ising, Wim Veling, Psychiatrie & Neuropsychologie, RS: FHML non-thematic output, RS: MHeNs School for Mental Health and Neuroscience, RS: MHeNs - R2 - Mental Health, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Adult Psychiatry, APH - Amsterdam Public Health, Other departments, Clinical Psychology, EMGO+ - Mental Health, EMGO - Mental health, and Epidemiology and Data Science
- Subjects
Adult ,Male ,Risk ,medicine.medical_specialty ,Pediatrics ,Psychosis ,cognitive behavior therapy ,medicine.medical_treatment ,Rate ratio ,ultra-high risk ,law.invention ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Randomized controlled trial ,prevention ,law ,Early Medical Intervention ,Outcome Assessment, Health Care ,medicine ,Humans ,Psychiatry ,Netherlands ,First episode ,Cognitive Behavioral Therapy ,At risk mental state ,Regular Article ,medicine.disease ,030227 psychiatry ,Cognitive behavioral therapy ,schizophrenia ,Psychiatry and Mental health ,Early Diagnosis ,Psychotic Disorders ,Schizophrenia ,at-risk mental state ,Disease Progression ,Number needed to treat ,Female ,Psychology ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Previously, we demonstrated that cognitive behavior therapy for ultra-high risk (called CBTuhr) halved the incidence of psychosis over an 18-month period. Follow-up data from the same study are used to evaluate the longer-term effects at 4 years post-baseline.The Dutch Early Detection and Intervention Evaluation study was a randomized controlled trial of 196 UHR patients comparing CBTuhr with treatment-as-usual (TAU) for comorbid disorders with TAU only. Of the original 196 patients, 113 consented to a 4-year follow-up (57.7%; CBTuhr = 56 vs TAU = 57). Over the study period, psychosis incidence, remission from UHR status, and the effects of transition to psychosis were evaluated.The number of participants in the CBTuhr group making the transition to psychosis increased from 10 at 18-month follow-up to 12 at 4-year follow-up whereas it did not change in the TAU group (n = 22); this still represents a clinically important (incidence rate ratio [IRR] = 12/22 = 0.55) and significant effect (F(1,5) = 8.09, P = .03), favoring CBTuhr. The odds ratio of CBTuhr compared to TAU was 0.44 (95% CI: 0.24-0.82) and the number needed to treat was 8. Moreover, significantly more patients remitted from their UHR status in the CBTuhr group (76.3%) compared with the TAU group (58.7%) [t(120) = 2.08, P = .04]. Importantly, transition to psychosis was associated with more severe psychopathology and social functioning at 4-year follow-up.CBTuhr to prevent a first episode of psychosis in persons at UHR of developing psychosis is still effective at 4-year follow-up. Our data also show that individuals meeting the formal criteria of a psychotic disorder have worse functional and social outcomes compared with non-transitioned cases.The trial is registered at Current Controlled Trials as trial number ISRCTN21353122 (http://controlled-trials.com/ISRCTN21353122/gaag).? The Author 2016. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
- Published
- 2016
30. Satisfaction and safety using dexmedetomidine or propofol sedation during endoscopic oesophageal procedures
- Author
-
Susan van Dieren, Jacques J. Bergman, Susanne Eberl, Benedikt Preckel, Markus W. Hollmann, Other Research, Graduate School, Anesthesiology, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Gastroenterology and Hepatology, Surgery, and AII - Amsterdam institute for Infection and Immunity
- Subjects
Adult ,Male ,Adolescent ,medicine.drug_class ,Sedation ,law.invention ,Hypnotic ,Young Adult ,03 medical and health sciences ,Esophagus ,0302 clinical medicine ,Patient satisfaction ,Randomized controlled trial ,030202 anesthesiology ,law ,Humans ,Hypnotics and Sedatives ,Medicine ,Dexmedetomidine ,Alfentanil ,Propofol ,Aged ,Aged, 80 and over ,business.industry ,Hemodynamics ,Endoscopy ,Middle Aged ,Anesthesiology and Pain Medicine ,Blood pressure ,Patient Satisfaction ,Anesthesia ,Female ,030211 gastroenterology & hepatology ,Patient Safety ,medicine.symptom ,business ,medicine.drug - Abstract
BACKGROUND Dexmedetomidine possesses anxiolytic and hypnotic properties without respiratory side-effects, making it theoretically an ideal sedative agent for endoscopic procedures. OBJECTIVE We aimed to compare satisfaction and safety among outpatients receiving sedation with dexmedetomidine or propofol for endoscopic oesophageal procedures. DESIGN A randomised controlled study. SETTING Endoscopic intervention suite at the Academic Medical Centre in Amsterdam, Netherlands. PARTICIPANTS Patients aged at least 18 years, and American Society of Anesthesiologists' physical status 1 to 3. INTERVENTION Total 63 patients were randomised to receive either dexmedetomidine (D) or propofol (P). Pain was treated with alfentanil in both groups. MAIN OUTCOME MEASURES The primary outcomes were patients' and endoscopists' satisfaction levels measured by validated questionnaires (1 = very dissatisfied; 7 = highly satisfied). A secondary outcome was safety, determined by blood pressure, heart rate and oxygen saturation during and after the procedure, and respiratory rate and noninvasive cardiac output during the procedure. RESULTS Satisfaction of patients [median (IQR); group D, 5.0 (3.75 to 5.75) vs. group P, 6.25 (5.3 to 6.5)] and satisfaction of gastroenterologists [group D, 5.0 (4.4 to 5.8) vs. group P, 6.0 (5.4 to 6.0)] were lower in group D (both P
- Published
- 2016
31. Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia
- Author
-
Axel Bohring, Tae Joon Cho, Chong Ae Kim, Teresa Neuhann, Lesley C. Adès, Débora Romeo Bertola, Irma E Veenstra-Knol, Eva Morava, Erin Carter, Deborah Krakow, Aideen M. McInerney-Leo, Dagmar Wieczorek, Andrew J. Sutherland-Smith, Zandra A. Jenkins, Elaine Fletcher, Philip B. Daniel, Andrew O.M. Wilkie, Emma M. Wade, Tim M. Strom, Matthew A. Brown, Timothy R. Morgan, Raoul C.M. Hennekam, Stephen P. Robertson, David Markie, Hans Christoph Duba, Emma L. Duncan, Paul Leo, Louise C. Wilson, Andrea Superti-Furga, Marie-Claude Addor, ANS - Cellular & Molecular Mechanisms, APH - Amsterdam Public Health, and Paediatric Genetics
- Subjects
0301 basic medicine ,Male ,MAP Kinase Signaling System ,Filamins ,NF-KAPPA-B ,FILAMIN-A ,030105 genetics & heredity ,Biology ,medicine.disease_cause ,MAP3K7 ,Osteochondrodysplasias ,Article ,ACTIVATION ,03 medical and health sciences ,OSTEOCLAST DIFFERENTIATION ,BINDING ,medicine ,Genetics ,FLNA ,Missense mutation ,Humans ,Genetics(clinical) ,PROTEIN-KINASE PATHWAYS ,Forehead ,Phosphorylation ,PROLINE HYDROXYLATION ,Genetics (clinical) ,Adaptor Proteins, Signal Transducing ,TAB2 ,Phenocopy ,Mutation ,MAP kinase kinase kinase ,Autophosphorylation ,NF-kappa B ,MAP Kinase Kinase Kinases ,Phenotype ,Adaptor Proteins, Signal Transducing/genetics ,Adaptor Proteins, Signal Transducing/metabolism ,Female ,Filamins/genetics ,Forehead/abnormalities ,MAP Kinase Kinase Kinases/genetics ,MAP Kinase Kinase Kinases/metabolism ,MAP Kinase Signaling System/genetics ,Mutation/genetics ,NF-kappa B/metabolism ,Osteochondrodysplasias/genetics ,Osteochondrodysplasias/metabolism ,Protein Binding ,Protein Multimerization ,Signal Transduction/genetics ,030104 developmental biology ,HIF-ALPHA ,Cancer research ,GROWTH ,Signal Transduction - Abstract
Frontometaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations, except for an increased tendency to form keloid scars. Using whole-exome sequencing and targeted Sanger sequencing in 19 FMD-affected individuals with no identifiable FLNA mutation, we identified mutations in two genes-MAP3K7, encoding transforming growth factor β (TGF-β)-activated kinase (TAK1), and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n = 15) de novo mutation (c.1454C>T [ p.Pro485Leu]) proximal to the coiled-coil domain of TAK1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A [p.Val100Glu], and c.502G>C [p.Gly168Arg]). Notably, the subjects with the latter three mutations had a milder FMD phenotype. An additional de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerize or bind TAB2, but it does increase TAK1 autophosphorylation and alter the activity of more than one signaling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore, they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex.
- Published
- 2016
32. The contribution of travel-related urban zones, cycling and pedestrian networks and green space to commuting physical activity among adults – a cross-sectional population-based study using geographical information systems
- Author
-
Heli Valkeinen, Thomas Abel, Leena Kopperoinen, Tomi Mäki-Opas, Katja Borodulin, Seppo Koskinen, Tommi Härkänen, Ritva Prättälä, Pekka Itkonen, Sakari Karvonen, Anton E. Kunst, Sari Stenholm, APH - Amsterdam Public Health, and Public and occupational health
- Subjects
Male ,Socioecological model ,Built environment ,Urban Population ,Poison control ,Transportation ,Walking ,Occupational safety and health ,0302 clinical medicine ,11. Sustainability ,Medicine ,030212 general & internal medicine ,Finland ,Travel ,education.field_of_study ,lcsh:Public aspects of medicine ,Middle Aged ,GIS ,Pedestrian zone ,8. Economic growth ,Female ,Population study ,Research Article ,Adult ,Employment ,Population ,610 Medicine & health ,030209 endocrinology & metabolism ,Pedestrian ,Environment ,Young Adult ,03 medical and health sciences ,Leisure Activities ,360 Social problems & social services ,Environmental health ,Humans ,education ,Exercise ,Recreation ,Aged ,Pedestrians ,Green space ,business.industry ,Public Health, Environmental and Occupational Health ,Transport-related physical activity ,lcsh:RA1-1270 ,Health Surveys ,Bicycling ,Cross-Sectional Studies ,Logistic Models ,Geographic Information Systems ,Residence ,Self Report ,business - Abstract
Background The current political agenda aims to promote active environments and physical activity while commuting to work, but research on it has provided mixed results. This study examines whether the proximity of green space and people’s residence in different travel-related urban zones contributes to commuting physical activity. Methods Population-based cross-sectional health examination survey, Health 2011 study, and geographical information system (GIS) data were utilized. The GIS data on green space and travel-related urban zones were linked to the individuals of the Health 2011 study, based on their home geocoordinates. Commuting physical activity was self-reported. Logistic regression models were applied, and age, gender, education, leisure-time and occupational physical activity were adjusted. Analyses were limited to those of working age, living in the core-urban areas of Finland and having completed information on commuting physical activity (n = 2 098). Results Home location in a pedestrian zone of a main centre (odds ratio = 1.63; 95 % confidence interval = 1.06–2.51) or a pedestrian zone of a sub-centre (2.03; 1.09–3.80) and higher proportion of cycling and pedestrian networks (3.28; 1.71–6.31) contributed to higher levels of commuting physical activity. The contribution remained after adjusting for all the environmental attributes and individuals. Based on interaction analyses, women living in a public transport zone were almost two times more likely to be physically active while commuting compared to men. A high proportion of recreational green space contributed negatively to the levels of commuting physical activity (0.73; 0.57–0.94) after adjusting for several background factors. Based on interaction analyses, individuals aged from 44 to 54 years and living in sub-centres, men living in pedestrian zones of sub-centres, and those individuals who are physically inactive during leisure-time were less likely to be physically active while commuting. Conclusions Good pedestrian and cycling infrastructure may play an important role in promoting commuting physical activity among the employed population, regardless of educational background, leisure-time and occupational physical activity. Close proximity to green space and a high proportion of green space near the home may not be sufficient to initiate commuting physical activity in Finland, where homes surrounded by green areas are often situated in car-oriented zones far from work places.
- Published
- 2016
33. Cognitive behaviour therapy for chronic fatigue syndrome: Differences in treatment outcome between a tertiary treatment centre in the United Kingdom and the Netherlands
- Author
-
Hans Knoop, Margreet Worm-Smeitink, Kimberley Goldsmith, Trudie Chalder, Jan F. Wiborg, Stephanie Nikolaus, Sheila Ali, APH - Amsterdam Public Health, and Medical Psychology
- Subjects
Adult ,Male ,medicine.medical_specialty ,Social adjustment ,medicine.medical_treatment ,Treatment outcome ,Tertiary Care Centers ,03 medical and health sciences ,0302 clinical medicine ,Physical functioning ,Surveys and Questionnaires ,medicine ,Chronic fatigue syndrome ,Humans ,Disabled Persons ,In patient ,030212 general & internal medicine ,Netherlands ,Social functioning ,Fatigue Syndrome, Chronic ,Cognitive Behavioral Therapy ,Cognitive behaviour therapy ,Treatment protocols ,Outcome prediction ,Middle Aged ,Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] ,medicine.disease ,United Kingdom ,030227 psychiatry ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,Cognitive therapy ,Physical therapy ,Female ,Psychology ,Follow-Up Studies ,Clinical psychology - Abstract
Objective:Cognitive behaviour therapy (CBT) reduces fatigue and disability in chronic fatigue syndrome (CFS). However, outcomes vary between studies, possibly because of differences in patient characteristics, treatment protocols, diagnostic criteria and outcome measures. The objective was to compare outcomes after CBT in tertiary treatment centres in the Netherlands (NL) and the United Kingdom (UK), using different treatment protocols but identical outcome measures, while controlling for differences in patient characteristics and diagnostic criteria.Methods:Consecutively referred CFS patients who received CBT were included (NL: n = 293, UK: n = 163). Uncontrolled effect sizes for improvement in fatigue (Chalder Fatigue Questionnaire), physical functioning (SF-36 physical functioning subscale) and social functioning (Work and Social Adjustment Scale) were compared. Multiple regression analysis was used to examine whether patient differences explained outcome differences between centres.Results:Effect sizes differed between centres for fatigue (Cohen's D NL = 1.74, 95% CI = 1.52–1.95; UK = 0.99, CI = 0.73–1.25), physical functioning (NL = 0.99, CI = 0.81–1.18; UK = 0.33, CI = 0.08–0.58) and social functioning (NL = 1.47, CI = 1.26–1.69; UK = 0.61, CI = 0.35–0.86). Patients in the UK had worse physical functioning at baseline and there were minor demographic differences. These could not explain differences in centre outcome.Conclusion:Effectiveness of CBT differed between treatment centres. Differences in treatment protocols may explain this and should be investigated to help further improve outcomes.
- Published
- 2016
34. Thyroid function testing in women who had a stillbirth
- Author
-
Gerrit van den Berg, Fleurisca J. Korteweg, Jan Jaap H. M. Erwich, Janna Nijkamp, Albertus Timmer, Henk Groen, Ben W.J. Mol, Patrick M.M. Bossuyt, Methods in Medicines evaluation & Outcomes research (M2O), Reproductive Origins of Adult Health and Disease (ROAHD), Value, Affordability and Sustainability (VALUE), APH - Amsterdam Public Health, 10 Public Health & Methodologie, and Obstetrics and Gynaecology
- Subjects
HYPERTHYROIDISM ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Thyrotropin ,Thyroid Function Tests ,Cohort Studies ,0302 clinical medicine ,Endocrinology ,SUBCLINICAL HYPOTHYROIDISM ,Pregnancy ,Prospective Studies ,Prospective cohort study ,INCREASED RISK ,reproductive and urinary physiology ,Netherlands ,Cause of death ,Subclinical infection ,MATERNAL HYPOTHYROXINEMIA ,OUTCOMES ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Thyroid disease ,Stillbirth ,female genital diseases and pregnancy complications ,Female ,Thyroid function ,hormones, hormone substitutes, and hormone antagonists ,Cohort study ,Adult ,medicine.medical_specialty ,endocrine system ,HYPOTHYROIDISM COMPLICATING PREGNANCY ,030209 endocrinology & metabolism ,Thyroid function tests ,CLASSIFICATION ,Young Adult ,03 medical and health sciences ,Hypothyroidism ,Internal medicine ,medicine ,Humans ,HYPERTENSION ,business.industry ,medicine.disease ,DYSFUNCTION ,Pregnancy Complications ,Thyroxine ,ANTIBODIES ,business - Abstract
ContextThyroid dysfunction is thought to be associated with stillbirth. Therefore, thyroid function is often recommended in the diagnostic investigations for stillbirth.ObjectiveWe aimed to evaluate the added value of thyroid function testing in the diagnostic investigations for stillbirth.Design and patientsA nationwide multicentre prospective cohort study in 1025 women who suffered stillbirth >20 weeks of gestation performed between 2002 and 2008. In each woman, an extensive diagnostic work-up was performed, including placental examination and autopsy. TSH and FT4 values below the 25th percentile or above the 975th percentile according local laboratory reference values were regarded as abnormal. Women with a history of thyroid disease were evaluated separately.Main outcome measuresThyroid function abnormalities in women with stillbirth.ResultsOf 1025 included women, 21 had a history of thyroid disease (2%). In the 875 with TSH and FT4 results and no history of thyroid disease, 10% had hypothyroxinemia, 46% subclinical hypothyroidism, 16% overt hypothyroidism and 15% subclinical hyperthyroidism. Women with a subclinical hyperthyroidism more often had a foetal death caused by foetal hydrops: 23% vs 29% (adjusted OR 103, 95% CI 25-42).ConclusionsWomen with a stillbirth had a slightly higher prevalence of overt hypothyroidism, subclinical hypothyroidism and hypothyroxinaemia compared to previous studies on thyroid dysfunction in pregnant women. Given the absence of a strong associations with the cause of stillbirth, and no demonstrated beneficial effects of treating thyroid dysfunction in these women, routine screening after stillbirth is not justified.
- Published
- 2016
35. Tobacco control policy and socio-economic inequalities in smoking in 27 European countries
- Author
-
Anton E. Kunst, Marc C. Willemsen, Jizzo R. Bosdriesz, Karien Stronks, Public and occupational health, APH - Amsterdam Public Health, RS: CAPHRI - R6 - Promoting Health & Personalised Care, and Health promotion
- Subjects
Adult ,Male ,Inequality ,Cross-sectional study ,media_common.quotation_subject ,medicine.medical_treatment ,Socio-economic status ,Models, Psychological ,Smoking cessation ,Toxicology ,03 medical and health sciences ,0302 clinical medicine ,Environmental health ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Tobacco control policy ,Occupations ,Socioeconomic status ,Health policy ,media_common ,Pharmacology ,030505 public health ,Eurobarometer ,business.industry ,Health Policy ,Tobacco control ,Smoking ,Middle Aged ,Europe ,Psychiatry and Mental health ,Cross-Sectional Studies ,Socioeconomic Factors ,Scale (social sciences) ,Educational Status ,Female ,0305 other medical science ,business - Abstract
Background Higher Tobacco Control Scale (TCS) scores, in the early 2000s were associated with higher smoking cessation rates across Europe, both among lower and higher educated people. We aimed to assess if this association held in recent years. Methods Repeated cross-sectional Eurobarometer surveys were used, in 27 European countries from 2006 to 2012 (study sample = 73,617 adults). We used multilevel regression to model associations between the TCS (ranging from 0 to 100, quantifying: tobacco price, smoke-free laws, mass-media campaigns, advertising bans, warning labels, and cessation support) and both smoking cessation and cigarettes smoked per day. We modelled associations according to respondents’ education and occupation, with adjustment for age, sex, and survey-wave. Results We found no association between the TCS and smoking cessation for lower or middle educated respondents, but we did find an association for higher educated respondents (OR: 1.13, 95%CI: 1.08 to 1.19). For smoking intensity, we observed no associations with the TCS for lower educated respondents (beta: 0.04, 95%CI: −0.33 to 0.41) but we did observe significant associations for middle (beta: −0.25, 95%CI: −0.47 to −0.03) and higher educated respondents (beta: −0.27, 95%CI: −0.55 to −0.01). Associations were observed for both manual and non-manual classes, but not for those not working for pay. Of the TCS domains, none were associated with smoking cessation for lower educated respondents, but five were for higher educated respondents. Conclusions Associations between tobacco control policies and smoking cessation were found mostly among higher socioeconomic groups. This underlines the need for specific tobacco control policies that explicitly focus on reaching low socio-economic groups.
- Published
- 2016
36. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health
- Author
-
Holger J. Schünemann, Reem Mustafa, Jan Brozek, Nancy Santesso, Pablo Alonso-Coello, Gordon Guyatt, Rob Scholten, Miranda Langendam, Mariska M. Leeflang, Elie A. Akl, Jasvinder A. Singh, Joerg Meerpohl, Monica Hultcrantz, Patrick Bossuyt, Andrew D. Oxman, Jasvinder Singh, Stefan Lange, Elena Parmelli, Jenny Moberg, Sarah Rosenbaum, Romina Brignardello-Petersen, Wojtek Wiercioch, Marina Davoli, Artur Nowak, Bart Dietl, Epidemiology and Data Science, APH - Amsterdam Public Health, and 10 Public Health & Methodologie
- Subjects
Test strategy ,medicine.medical_specialty ,Educational measurement ,Process management ,Epidemiology ,Computer science ,media_common.quotation_subject ,Guidelines as Topic ,Guidelines ,Recommendations ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,030212 general & internal medicine ,Grading (education) ,media_common ,Evidence-Based Medicine ,Education, Medical ,Management science ,Tests ,Public health ,Guideline ,Evidence-based medicine ,Certainty ,Clinical Practice ,GRADE ,GRADEpro ,Clinical Competence ,Educational Measurement ,Public Health ,Summary of findings ,Decision-making - Abstract
Objectives: To describe the grading of recommendations assessment, development and evaluation (GRADE) interactive evidence to decision (EtD) frameworks for tests and test strategies for clinical, public health, or coverage decisions. Study Design and Setting: As part of the GRADE Working Group's DECIDE project, we conducted workshops, user testing with systematic review authors, guideline developers and other decision makers, and piloted versions of the EtD framework. Results: EtD frameworks for tests share the structure, explicitness, and transparency of other EtD frameworks. They require specifying the purpose of the test, linked or related management, and the key outcomes of concern for different test results and subsequent management. The EtD criteria address test accuracy and assessments of the certainty of the additional evidence necessary for decision making. When there is no direct evidence of test effects on patient-important outcomes, formal or informal modeling is needed to estimate effects. We describe the EtD criteria based on examples developed with GRADEpro (www.gradepro.org), GRADE's software that also allows development and dissemination of interactive summary of findings tables. Conclusion: EtD frameworks for developing recommendations and making decisions about tests lay out the sequential steps in reviewing and assessing the different types of evidence that need to be linked. (C) 2016 Elsevier Inc. All rights reserved.
- Published
- 2016
37. Socioeconomic Differences in Informed Decisions About Down Syndrome Screening: A Systematic Review and Research Agenda
- Author
-
Mariana S. Sousa, Mirjam P. Fransen, Marie-Louise Essink-Bot, Jane Halliday, Sian K Smith, Michelle Peate, Public and occupational health, and APH - Amsterdam Public Health
- Subjects
Gerontology ,Health (social science) ,MEDLINE ,Health literacy ,CINAHL ,PsycINFO ,Library and Information Sciences ,Choice Behavior ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Pregnancy ,law ,Informed consent ,Numeracy ,Prenatal Diagnosis ,Humans ,Medicine ,030212 general & internal medicine ,Socioeconomic status ,Randomized Controlled Trials as Topic ,Informed Consent ,030219 obstetrics & reproductive medicine ,business.industry ,Communication ,Public Health, Environmental and Occupational Health ,Socioeconomic Factors ,0807 Library and Information Studies, 1117 Public Health and Health Services, 2001 Communication and Media Studies ,Female ,Public Health ,Down Syndrome ,business ,Social psychology - Abstract
Supporting pregnant women to make informed choices about Down syndrome screening is widely endorsed. We reviewed the literature on: (a) the association between socioeconomic position and informed choices and decision-making about Down syndrome screening, and (b) the possible mediating variables (e.g., health literacy, numeracy skills, behavioral and communication variables) that might explain the relationship. EMBASE, MEDLINE, PubMed, CINAHL, and PsycINFO were searched from January 1999 to September 2014. The methodological quality of studies was determined by predefined criteria regarding the research aims, study design, study population and setting, measurement tools, and statistical analysis. A total of 33 studies met the inclusion criteria. Women from lower socioeconomic groups experience greater difficulties making informed choices about Down syndrome screening compared to women from higher socioeconomic groups. Most studies focus on individual dimensions of informed decision-making rather than assessing elements in conjunction with one another. Few studies have explored why there are socioeconomic differences in women's ability to make informed screening decisions. Future work is needed to identify mediating variables in this pathway. Systematic evidence-based intervention development to improve communication, understanding, and decision-making about Down syndrome screening is needed to ensure that women have an equal opportunity to make an informed choice about screening regardless of their socioeconomic position.
- Published
- 2016
38. Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia
- Author
-
Wim J. E. Tissing, Marc Bierings, Femke K. Aarsen, Cor van den Bos, Christian M. Zwaan, Helene Thygesen, Marry M. van den Heuvel-Eibrink, Rob Pieters, Margreet A. Veening, Erica L T van den Akker, Saskia M. F. Pluijm, Lidewij T. Warris, CCA -Cancer Center Amsterdam, APH - Amsterdam Public Health, Paediatric Oncology, Pediatrics, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Pediatric surgery, and CCA - Clinical Therapy Development
- Subjects
PREDNISONE ,PROTOCOL ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Hydrocortisone ,CORTICOSTEROIDS ,CHILDHOOD ,QUESTIONNAIRE ,CHILDREN ,Placebo ,Dexamethasone ,VALIDATION ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,QUALITY-OF-LIFE ,Prednisone ,law ,Journal Article ,medicine ,Humans ,Child ,Adverse effect ,Cross-Over Studies ,business.industry ,SLEEP DISTURBANCES ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Crossover study ,Multicenter Study ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Randomized Controlled Trial ,HEALTH ,Sleep ,business ,Psychosocial ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Purpose Dexamethasone is a key component in the treatment of pediatric acute lymphoblastic leukemia (ALL), but can induce serious adverse effects. Recent studies have led to the hypothesis that neuropsychological adverse effects may be a result of cortisol depletion of the cerebral mineralocorticoid receptors. We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL. Patients and Methods We performed a multicenter, double-blind, randomized controlled trial with a crossover design. Of 116 potentially eligible patients (age 3 to 16 years), 50 were enrolled and were treated with two consecutive courses of dexamethasone in accordance with Dutch Childhood Oncology Group ALL protocols. Patients were randomly assigned to receive either hydrocortisone or placebo in a circadian rhythm (10 mg/m2/d) during both dexamethasone courses. Primary outcome measure was parent-reported Strength and Difficulties Questionnaire in Dutch, which assesses psychosocial problems. Other end points included questionnaires, neuropsychological tests, and metabolic parameters. Results Of 48 patients who completed both courses, hydrocortisone had no significant effect on outcome; however, a more detailed analysis revealed that in 16 patients who developed clinically relevant psychosocial adverse effects, addition of hydrocortisone substantially reduced their Strength and Difficulties Questionnaire in Dutch scores in the following domains: total difficulties, emotional symptoms, conduct problems, and impact of difficulties. Moreover, in nine patients who developed clinically relevant, sleep-related difficulties, addition of hydrocortisone reduced total sleeping problems and disorders of initiating and maintaining sleep. In contrast, hydrocortisone had no effect on metabolic parameters. Conclusion Our results suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the occurrence of serious neuropsychological adverse effects and sleep-related difficulties in pediatric patients with ALL.
- Published
- 2016
39. Variation of 46 Innate Immune Genes Evaluated for their Contribution in Pneumococcal Meningitis Susceptibility and Outcome
- Author
-
Arie van der Ende, Mercedes Valls Serón, Frank Baas, Madelijn Geldhoff, Diederik van de Beek, Bart Ferwerda, Aeilko H. Zwinderman, Aldo Jongejan, Matthijs C. Brouwer, ANS - Neuroinfection & -inflammation, Neurology, AII - Amsterdam institute for Infection and Immunity, Epidemiology and Data Science, APH - Amsterdam Public Health, Medical Microbiology and Infection Prevention, and Human Genetics
- Subjects
0301 basic medicine ,Male ,MDS, multidimensional scaling ,lcsh:Medicine ,Disease ,CSF, cerebrospinal fluid ,0302 clinical medicine ,PCR, polymerase chain reaction ,Gene Frequency ,NOD2 ,LTA, lipoteichoic acid ,Genotype ,Exome ,Prospective Studies ,Innate immunity ,lcsh:R5-920 ,RVIS, residual variation intolerance score ,Meningitis, Pneumococcal ,High-Throughput Nucleotide Sequencing ,General Medicine ,SKAT, SNP-set (Sequence) Kernel Association Test ,Middle Aged ,Prognosis ,3. Good health ,Streptococcus pneumoniae ,Cytokines ,Female ,Disease Susceptibility ,lcsh:Medicine (General) ,Meningitis ,Research Paper ,IRAK4 ,Biology ,GATK, genome analysis tool kit ,NRLBM, Netherlands Reference Laboratories For Bacterial Meningitis ,MAF, minor allele frequency ,Polymorphism, Single Nucleotide ,General Biochemistry, Genetics and Molecular Biology ,TLR, Toll-like receptors ,03 medical and health sciences ,Immune system ,Genetic variation ,PAMPS, pathogen-associated molecular pattern molecules ,medicine ,Humans ,Genetic Predisposition to Disease ,Alleles ,Aged ,FDR, False Discovery Rate ,Innate immune system ,HWE, Hardy–Weinberg equilibrium ,lcsh:R ,Haplotype ,Genetic Variation ,Pneumococcal meningitis ,medicine.disease ,NLRs, NOD-like receptors ,Immunity, Innate ,OR, odds ratio ,Patient Outcome Assessment ,030104 developmental biology ,GOS, Glasgow Outcome Scale ,Haplotypes ,Case-Control Studies ,Immunology ,IPD, invasive pneumococcal disease ,030217 neurology & neurosurgery ,Genome-Wide Association Study - Abstract
Pneumococcal meningitis is the most common and severe form of bacterial meningitis. Early recognition of the pathogen and subsequent innate immune response play a vital role in disease susceptibility and outcome. Genetic variations in innate immune genes can alter the immune response and influence susceptibility and outcome of meningitis disease. Here we conducted a sequencing study of coding regions from 46 innate immune genes in 435 pneumococcal meningitis patients and 416 controls, to determine the role of genetic variation on pneumococcal meningitis susceptibility and disease outcome. Strongest signals for susceptibility were rs56078309 CXCL1 (p = 4.8e − 04) and rs2008521 in CARD8 (p = 6.1e − 04). For meningitis outcome the rs2067085 in NOD2 (p = 5.1e − 04) and rs4251552 of IRAK4 were the strongest associations with unfavorable outcome (p = 6.7e − 04). Haplotype analysis showed a haplotype block, determined by IRAK4 rs4251552, significantly associated with unfavorable outcome (p = 0.004). Cytokine measurements from cerebrospinal fluid showed that with the IRAK4 rs4251552 G risk allele had higher levels of IL-6 compared to individuals with A/A genotype (p = 0.04). We show that genetic variation within exons and flanking regions of 46 innate immunity genes does not yield significant association with pneumococcal meningitis. The strongest identified signal IRAK4 does imply a potential role of genetic variation in pneumococcal meningitis., Highlights • Exome variations of 46 innate immune genes show no association with pneumococcal meningitis susceptibility and outcome. • Variations that have previously been associated with invasive pneumococcal disease or meningitis could not be replicated. • Highest signals found were variations in CXCL1 and CARD8 for susceptibility and NOD2 and IRAK4 for outcome. • The IRAK4 rs4251552 variant shows a trend where patients with a G-allele have higher IL-6 levels in their liquor. The pneumococcus is the most common causative pathogen of bacterial meningitis. We investigated the association of genetic variation within the coding sequences and flanking intronic regions of 46 innate immunity genes. These genes are responsible for our first line of defense during invading pathogens. In a cohort of 435 pneumococcal meningitis patients and 416 controls we found that variation within CXCL1 and CARD8 were the strongest signals associated with pneumococcal meningitis susceptibility. For disease severity we identified variations in NOD2 and IRAK4 genes to be associated with outcome. These findings can help in the understanding and treatment of pneumococcal meningitis.
- Published
- 2016
40. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients
- Author
-
Mohammad R. Toliat, Brendon P. Scicluna, Janneke Horn, Peter M. C. Klein Klouwenberg, Aeilko H. Zwinderman, Marc J. M. Bonten, Lonneke A. van Vught, Marek Franitza, Olaf L. Cremer, David S. Y. Ong, Peter Nürnberg, Tom van der Poll, Theodora A. M. Claushuis, Arie J. Hoogendijk, Marcus J. Schultz, Maryse A. Wiewel, Graduate School, Center of Experimental and Molecular Medicine, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Epidemiology and Data Science, Medical Microbiology and Infection Prevention, ANS - Neuroinfection & -inflammation, Intensive Care Medicine, and Infectious diseases
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Critical Illness ,medicine.medical_treatment ,Immunology ,Biochemistry ,law.invention ,Sepsis ,Pathogenesis ,03 medical and health sciences ,law ,Internal medicine ,Journal Article ,medicine ,Humans ,Platelet ,Survival analysis ,Aged ,Hematology ,Platelet Count ,business.industry ,Case-control study ,Cell Biology ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Thrombocytopenia ,Intensive care unit ,Intensive Care Units ,030104 developmental biology ,Cytokine ,Case-Control Studies ,Cytokines ,Female ,business ,Biomarkers - Abstract
Preclinical studies have suggested that platelets influence the host response during sepsis. We sought to assess the association of admission thrombocytopenia with the presentation, outcome, and host response in patients with sepsis. Nine hundred thirty-one consecutive sepsis patients were stratified according to platelet counts (very low
- Published
- 2016
41. Hysteroscopy before in-vitro fertilisation (inSIGHT): a multicentre, randomised controlled trial
- Author
-
Janet Kwee, G.J. Scheffer, Frank J. M. Broekmans, Carolien A.M. Koks, Annemiek W. Nap, Jenneke C. Kasius, Ramon H. M. Dykgraaf, Eugenie M. Kaaijk, Jaap Friederich, Benedictus C. Schoot, Annemieke Hoek, Femke Mol, Corry H. de Koning, Kathrin Fleischer, Helen L. Torrance, Arne M. van Heusden, Leonie A. Louwe, Ronald J T van Golde, Walter K. H. Kuchenbecker, Ineke C. A. H. Janssen, Alexander V. Sluijmer, Marinus J.C. Eijkemans, Janine G. Smit, Marcel H.A van Hooff, Ben W.J. Mol, Petra A. P. Manger, Denise A. M. Perquin, Obstetrics & Gynecology, Obstetrie & Gynaecologie, RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), Reproductive Origins of Adult Health and Disease (ROAHD), ARD - Amsterdam Reproduction and Development, Center for Reproductive Medicine, APH - Amsterdam Public Health, and Obstetrics and Gynaecology
- Subjects
Time Factors ,medicine.medical_treatment ,Intracytoplasmic sperm injection ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,Pregnancy ,law ,Obstetrics and Gynaecology ,OFFICE HYSTEROSCOPY ,030212 general & internal medicine ,Non-U.S. Gov't ,reproductive and urinary physiology ,Netherlands ,Medicine(all) ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Obstetrics ,Research Support, Non-U.S. Gov't ,Obstetrics and Gynecology ,General Medicine ,Multicenter Study ,Treatment Outcome ,medicine.anatomical_structure ,IVF ,Hysteroscopy ,Randomized Controlled Trial ,Female ,Uterine cavity ,Live birth ,Infertility, Female ,Live Birth ,ASSISTED REPRODUCTION ,SONOHYSTEROGRAPHY ,Adult ,medicine.medical_specialty ,Fertilization in Vitro ,Research Support ,03 medical and health sciences ,Journal Article ,medicine ,Humans ,DIAGNOSTIC-ACCURACY ,ENDOMETRIAL RECEPTIVITY ,UTERINE CAVITY ,Gynecology ,Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7] ,TRANSVAGINAL SONOGRAPHY ,Intention-to-treat analysis ,In vitro fertilisation ,business.industry ,Myoma ,medicine.disease ,PREGNANCY RATES ,Ambulatory Surgical Procedures ,Relative risk ,IMPLANTATION ,business - Abstract
Since the first successful live birth after in vitro fertilization (IVF) was reported in 1978, more than 5 million children have been born with the help of this and intracytoplasmic sperm injection (ICSI) procedures. However, only approximately 25% to 30% of cycles of IVF and ICSI lead to the birth of a child. The reasons for implantation failure are poorly understood. One major cause of implantation failure is abnormalities of the uterine cavity such as polyps, myoma, and adhesions. Hysteroscopy has been generally regarded as the standard procedure to detect these uterine abnormalities. It is thought to improve pregnancy rates in women scheduled for IVF by detection and surgical removal of uterine cavity abnormalities, dilatation of the cervical canal, or induction of inflammatory reactions in the endometriumby the procedure itself. Hysteroscopy is often performed routinely in infertile women scheduled for their first IVF cycle. However, there are no data from well-designed randomized controlled trials to support this practice. The inSIGHT trial is a pragmatic multicenter randomized clinical trial designed to determine whether routine hysteroscopy before the first IVF treatment cycle increases the live birth rate. The trial was conducted in 7 university hospitals and 15 large general hospitals in the Netherlands. Women eligible for the trial were infertile, scheduled to start their first IVF or ICSI treatment, had no previous hysteroscopy, and had a normal transvaginal ultrasound of the uterine cavity. Subjects were randomly assigned in a 1: 1 ratio to hysteroscopy with treatment of detected intracavitary abnormalities before starting IVF followed by IVF (hysteroscopy group) or to immediate start of IVF treatment (immediate IVF group). Web-based randomization was done with a variable block size to allocate patients to groups and was stratified by center. The doctors, outcome assessors, and participants were not masked to the assigned group. The primary study outcome was an ongoing pregnancy (detection of a fetal heartbeat at > 12weeks of gestation) within 18 months of randomization and a live birth. Analysis was done according to intention to treat. Between May 25, 2011, and August 27, 2013, 750 women were randomized: 373 to the hysteroscopy group and 377 to the immediate IVF group. A live birth occurred during the trial period in 209 (57%) of 369 women in the hysteroscopy group and 200 (54%) of 373 in the immediate IVF group; the relative riskwas 1.06, with a 95% confidence interval of 0.93 to 1.20; P = 0.41. These findings demonstrate that hysteroscopy does not improve live birth rates in infertile women scheduled for their first IVF cycle, who have a normal transvaginal ultrasound of the uterine cavity. Therefore, routine hysteroscopy should not be performed in women with a normal transvaginal ultrasound.
- Published
- 2016
42. Improving GRADE evidence tables part 2: a systematic survey of explanatory notes shows more guidance is needed
- Author
-
Reem A. Mustafa, Toby J Lasserson, Holger J. Schünemann, Romina Brignardello-Petersen, Rasmus Moustgaard, Matthew Ventresca, Jan Brozek, Nancy Santesso, Miranda W. Langendam, Pauline Heus, Alonso Carrasco-Labra, APH - Amsterdam Public Health, and Epidemiology and Data Science
- Subjects
Research Report ,Technology Assessment, Biomedical ,Epidemiology ,Systematic survey ,Applied psychology ,Information Dissemination ,Guidelines as Topic ,Judgment ,03 medical and health sciences ,0302 clinical medicine ,Statistics ,Journal Article ,Humans ,Medicine ,030212 general & internal medicine ,Health technology assessment ,Quality of evidence ,Grading (education) ,Evidence-Based Medicine ,business.industry ,Summary of findings tables ,Health technology ,Systematic reviews ,Evidence-based medicine ,Risk of bias ,Review Literature as Topic ,GRADE ,GRADEpro ,Systematic review ,Observational study ,business ,030217 neurology & neurosurgery - Abstract
Objectives The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group has developed GRADE evidence profiles (EP) and summary of findings (SoF) tables to present evidence summaries in systematic reviews, clinical guidelines, and health technology assessments. Explanatory notes are used to explain choices and judgments in these summaries, for example, on rating of the quality of evidence. Study Design and Setting A systematic survey of the explanations in SoF tables in 132 randomly selected Cochrane Intervention reviews and in EPs of 10 guidelines. We analyzed the content of 1,291 explanations using a predefined list of criteria. Results Most explanations were used to describe or communicate results and to explain downgrading of the quality of evidence, in particular for risk of bias and imprecision. Addressing the source of baseline risk (observational data or control group risk) was often missing. For judgments about downgrading the quality of evidence, the percentage of informative explanations ranged between 41% (imprecision) and 79% (indirectness). Conclusion We found that by and large explanations were informative but detected several areas for improvement (e.g., source of baseline risk and judgments on imprecision). Guidance about explanatory footnotes and comments will be provided in the last article in this series.
- Published
- 2016
43. Mortality risk in European children with end-stage renal disease on dialysis
- Author
-
Franz Schaefer, Ilona Zagozdzon, Jaap W. Groothoff, Dusan Paripovic, James G. Heaf, Nicholas C. Chesnaye, Kitty J. Jager, György Reusz, Malcolm Lewis, Karlijn J. van Stralen, Elisabeth Maurer, Marjolein Bonthuis, APH - Amsterdam Public Health, Medical Informatics, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Paediatric Nephrology, ACS - Amsterdam Cardiovascular Sciences, and Other departments
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,Population ,030232 urology & nephrology ,030204 cardiovascular system & hematology ,Infections ,End stage renal disease ,Peritoneal dialysis ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Renal Dialysis ,Risk Factors ,medicine ,Humans ,Registries ,Child ,Propensity Score ,education ,Survival rate ,Dialysis ,Proportional Hazards Models ,education.field_of_study ,business.industry ,Mortality rate ,Hazard ratio ,Age Factors ,Infant, Newborn ,Infant ,3. Good health ,Europe ,Survival Rate ,Cardiovascular Diseases ,Nephrology ,Child, Preschool ,Kidney Failure, Chronic ,Female ,Hemodialysis ,business ,Peritoneal Dialysis - Abstract
We aimed to describe survival in European pediatric dialysis patients and compare the differential mortality risk between patients starting on hemodialysis (HD) and peritoneal dialysis (PD). Data for 6473 patients under 19 years of age or younger were extracted from the European Society of Pediatric Nephrology, the European Renal Association, and European Dialysis and Transplant Association Registry for 36 countries for the years 2000 through 2013. Hazard ratios (HRs) were adjusted for age at start of dialysis, sex, primary renal disease, and country. A secondary analysis was performed on a propensity score-matched (PSM) cohort. The overall 5-year survival rate in European children starting on dialysis was 89.5% (95% confidence interval [CI] 87.7%-91.0%). The mortality rate was 28.0 deaths per 1000 patient years overall. This was highest (36.0/1000) during the first year of dialysis and in the 0- to 5-year age group (49.4/1000). Cardiovascular events (18.3%) and infections (17.0%) were the main causes of death. Children selected to start on HD had an increased mortality risk compared with those on PD (adjusted HR 1.39, 95% CI 1.06-1.82, PSM HR 1.46, 95% CI 1.06-2.00), especially during the first year of dialysis (HD/PD adjusted HR 1.70, 95% CI 1.22-2.38, PSM HR 1.79, 95% CI 1.20-2.66), when starting at older than 5 years of age (HD/PD: adjusted HR 1.58, 95% CI 1.03-2.43, PSM HR 1.87, 95% CI 1.17-2.98) and when children have been seen by a nephrologist for only a short time before starting dialysis (HD/PD adjusted HR 6.55, 95% CI 2.35-18.28, PSM HR 2.93, 95% CI 1.04-8.23). Because unmeasured case-mix differences and selection bias may explain the higher mortality risk in the HD population, these results should be interpreted with caution.
- Published
- 2016
44. Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma
- Author
-
Georges-Pascal Haber, Hiury S. Andrade, Homayoun Zargar, Daniel Ramirez, Jihad H. Kaouk, Peter A. Caputo, Onder Kara, Robert J. Stein, Oktay Akca, CCA -Cancer Center Amsterdam, APH - Amsterdam Public Health, and Urology
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Comorbidity ,Kaplan-Meier Estimate ,Nephrectomy ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Robotic Surgical Procedures ,Renal cell carcinoma ,Interquartile range ,medicine ,Humans ,Carcinoma, Renal Cell ,Survival rate ,Aged ,Retrospective Studies ,business.industry ,Margins of Excision ,Retrospective cohort study ,Odds ratio ,Perioperative ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Tumor Burden ,Surgery ,Survival Rate ,030220 oncology & carcinogenesis ,Female ,business ,Organ Sparing Treatments ,Follow-Up Studies ,Kidney disease - Abstract
Background Robotic partial nephrectomy (RPN) is established as a minimally invasive nephron-sparing technique with excellent perioperative and intermediate oncologic outcomes. However, long-term oncologic outcomes have not been reported to date. Objective To report long-term oncologic outcomes of RPN. Design, setting, and participants Consecutive patients undergoing RPN from June 2006 to March 2010 were selected from our prospective RPN database. Patients with benign tumors, prior ipsilateral PN, or prior radical nephrectomy and those with follow-up of Intervention Transperitoneal RPN. Outcomes measurements and statistical analysis Demographic, perioperative, and postoperative data were analyzed. Overall survival (OS), cancer-free survival (CFS), and cancer-specific survival (CSS) were evaluated using Kaplan-Meier survival analysis. Univariate logistic regression analysis for overall mortality was performed to evaluate the odds ratio (OR) for variables of interest. Results and limitations In total, 115 RPNs for RCC were performed in 110 patients. The mean age was 59.8±11.0 yr and the median age-adjusted Charlson comorbidity index (ACCI) was 4 (interquartile range [IQR] 3–5). The median tumor size was 2.6cm (IQR 2.0–3.7) and median RENAL score was 7 (IQR 6–9). Clear cell carcinoma was present in 67.8% of cases, and two cases (1.7%) had positive surgical margins. Glomerular filtration rate preservation was 87.8% (IQR 74.9–98.1), which translates to 19.1% chronic kidney disease upstaging. The median follow-up was 61.9 mo (IQR 50.9–71.4) and the 5-yr OS, CFS, and CSS were 91.1%, 97.8%, and 97.8%, respectively. On univariable logistic regression, ACCI was the only factor associated with a higher risk of overall mortality (OR 1.67, p =0.006). The retrospective design, the high surgical volume at our institution, and the potential selection bias with careful patient selection early in the RPN experience may limit the generalizability of our findings. Conclusions This is the first study confirming excellent long-term oncologic outcomes after RPN in a selected cohort of patients. Patient summary Robotic partial nephrectomy is a relatively recently developed treatment for renal cell carcinoma. This study confirms its safety and reports excellent long-term cancer control.
- Published
- 2016
45. A power analysis for future clinical trials on the potential adverse effects of SSRIs on amygdala reactivity
- Author
-
Marco A. Bottelier, M.B. de Ruiter, Liesbeth Reneman, Anouk Schrantee, H. G. Ruhé, G. van Wingen, Graduate School, ANS - Amsterdam Neuroscience, Radiology and Nuclear Medicine, ANS - Compulsivity, Impulsivity & Attention, APH - Personalized Medicine, ANS - Brain Imaging, Adult Psychiatry, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, and APH - Amsterdam Public Health
- Subjects
Oncology ,medicine.medical_specialty ,Population ,Biology ,Placebo ,Amygdala ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Genetics ,medicine ,SSRI ,education ,Ecology, Evolution, Behavior and Systematics ,Fluoxetine ,education.field_of_study ,Ecology ,Emotional dysregulation ,anxiety ,030227 psychiatry ,Clinical trial ,medicine.anatomical_structure ,depression ,adverse effects ,Anxiety ,medicine.symptom ,030217 neurology & neurosurgery ,Biotechnology ,medicine.drug ,amygdala reactivity - Abstract
Treatment of adolescents with antidepressants may induce an increased risk for suicidality in this population. The activity of the amygdala during processing of emotional faces with functional Magnetic Resonance Imaging (fMRI) is a well-known measure of emotional dysregulation. Based upon data of our prematurely ended randomized clinical trial with fluoxetine (NTR3103) in anxious and or depressed girls (12–14 years of age) we calculated that with the found effect size of r = 0.66, compared to placebo, only 8 subjects are needed to demonstrate increased amygdala activity following 16 weeks of treatment with fluoxetine.
- Published
- 2016
46. Time to publication among completed diagnostic accuracy studies: associated with reported accuracy estimates
- Author
-
Aeilko H. Zwinderman, Jérémie F. Cohen, Nick van Es, Daniël A. Korevaar, Patrick M.M. Bossuyt, Epidemiology and Data Science, Graduate School, APH - Amsterdam Public Health, APH - Methodology, APH - Personalized Medicine, and 10 Public Health & Methodologie
- Subjects
medicine.medical_specialty ,Time lag bias ,Time Factors ,Epidemiology ,Trial registration ,Review Literature as Topic ,Health Informatics ,Diagnostic accuracy ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Meta-Analysis as Topic ,Internal medicine ,Statistics ,medicine ,Humans ,030212 general & internal medicine ,Diagnostic Errors ,Proportional Hazards Models ,lcsh:R5-920 ,Proportional hazards model ,business.industry ,Hazard ratio ,Research waste ,Study Characteristics ,Systematic review ,Sensitivity and specificity ,Reporting bias ,Median time ,business ,lcsh:Medicine (General) ,Research Article - Abstract
Background Previous evaluations have documented that studies evaluating the effectiveness of therapeutic interventions are not always reported, and that those with statistically significant results are published more rapidly than those without. This can lead to reporting bias in systematic reviews and other literature syntheses. We evaluated whether diagnostic accuracy studies that report promising results about the performance of medical tests are also published more rapidly. Methods We obtained all primary diagnostic accuracy studies included in meta-analyses of Medline-indexed systematic reviews that were published between September 2011 and January 2012. For each primary study, we extracted estimates of diagnostic accuracy (sensitivity, specificity, Youden’s index), the completion date of participant recruitment, and the publication date. We calculated the time from completion to publication and assessed associations with reported accuracy estimates. Results Forty-nine systematic reviews were identified, containing 92 meta-analyses and 924 unique primary studies, of which 756 could be included. Study completion dates were missing for 285 (38 %) of these. Median time from completion to publication in the remaining 471 studies was 24 months (IQR 16 to 35). Primary studies that reported higher estimates of sensitivity (Spearman’s rho = −0.14; p = 0.003), specificity (rho = −0.17; p
- Published
- 2016
47. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
- Author
-
Silvio Danese, V. Yajnik, P. Gionchetti, Brian G. Feagan, Richard N. Fedorak, O. Dewit, D. Sorrentino, V. F. Annese, W J Sandborn, Michael Chiorean, G. Radford-Smith, S Plevy, I. Lawrance, Jane E. Onken, Simon Campbell, Jewel Johanns, Peter L. Lakatos, G R D’Haens, Denis Franchimont, J. C. Preiss, Giovanni Terrosu, Áron Vincze, Torsten Kucharzik, Charles Randall, I. Stein, Edward V. Loftus, L. Sauberman, X. Li, I. Oikonomou, Frank Zerbib, H. G. Lamprecht, R. Kottoor, J. Vecchio, Severine Vermeire, Daniel Rachmilewitz, J. R. Lachance, J.L. Dupas, W. H. Holderman, Michael Safdi, T. Haas, J.-F. Colombel, Richard B. Gearry, Russell S. Walmsley, R. P. Phillips, Miguel Regueiro, A. B. Hawthorne, David T. Rubin, J. W. Hamilton, G. D'Haens, M Parkes, Jean-Marie Reimund, Fabrizio Bossa, Walter Reinisch, K. A. Peterson, M. Ropeleski, S. Fishman, Marc Chevrier, Hans H Herfarth, Stephen B. Hanauer, Timothy H. Florin, Walter Fries, D. J. Hetzel, D. E. Elliott, János Banai, B. W. Behm, S. Sedghi, Remo Panaccione, Peter D.R. Higgins, Jean-Paul Achkar, Ziad Younes, Raja Atreya, Harald Vogelsang, M. Noar, S. S. Dhalla, U. Boecker, Raymond Bourdages, Ellen Scherl, Eran Goldin, T. Ritter, S. Gassner, Stefanie Howaldt, M. Ricci, Paolo Gionchetti, B. I. Leman, Marion Blank, D. Grunkmeier, Livia Biancone, J. Mudter, N. Chiba, Paolo Usai, R. Hardi, I. P. Beales, István Altorjay, W. J S Devilliers, J. Hill, Daniel C. Baumgart, Jason M. Swoger, Charles A. Sninsky, B. Singh Salh, L. D. Wruble, G. Bramkamp, Dario Sorrentino, Paul Rutgeerts, Stephen J. Bickston, S. Schreiber, D. J. Helper, Eric Lerebours, Jaroslaw Regula, M. D. Kreines, M. Strasser, C. Antoni, Giovanni Maconi, Freddy Cornillie, Laurent Peyrin-Biroulet, J. S. Hanson, Ewa Małecka-Panas, David Rowbotham, Jean-Charles Grimaud, Gerald Fraser, Ursula Seidler, C. Bünning, C. Berg, G. Reicht, Martin Lukas, John W. Popp, Edouard Louis, D. Laharie, Xavier Hébuterne, K. J. Brown, Márta Varga, L. Paradowski, Robert Ehehalt, Sandro Ardizzone, Stephanie Viennot, S. B. Hanauer, Charles N. Bernstein, Milan Lukas, H. Debinski, R. P. Schwarz, Simon Travis, D. I. Weinberg, D. Wallace, R. S. Stubbs, Bin Zou, A. Sloss, John Wyeth, Irit Avni-Biron, Peter Bossuyt, Ira Shafran, Matthieu Allez, Pierre Desreumaux, Michael Schultz, W. Reinisch, William J. Sandborn, APH - Amsterdam Public Health, 10 Public Health & Methodologie, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, AII - Amsterdam institute for Infection and Immunity, Intensive Care Medicine, UCL - SSS/IREC-Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN-Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Regueiro, M, Feagan, Bg, Zou, B, Johanns, J, Blank, Ma, Chevrier, M, Plevy, S, Popp, J, Cornillie, Fj, Lukas, M, Danese, S, Gionchetti, P, Hanauer, Sb, Reinisch, W, Sandborn, Wj, Sorrentino, D, Rutgeerts, P, Regueiro, Miguel, Feagan, Brian G., Zou, Bin, Johanns, Jewel, Blank, Marion A., Chevrier, Marc, Plevy, Scott, Popp, John, Cornillie, Freddy J., Lukas, Milan, Danese, Silvio, Gionchetti, Paolo, Hanauer, Stephen B., Reinisch, Walter, Sandborn, William J., Sorrentino, Dario, Rutgeerts, Paul, Debinski, H., Florin, T., Hetzel, D., Lawrance, I., Radford Smith, G., Sloss, A., Sorrentino, D., Gassner, S., Haas, T., Reicht, G., Reinisch, W., Strasser, M., Vogelsang, H., Bossuyt, P., Dewit, O., D'Haens, G., Franchimont, D., Louis, E., Vermeire, S., Bernstein, C. N., Bourdages, R., Chiba, N., Dhalla, S. S., Feagan, B. G., Fedorak, R. N., Lachance, J. R., Panaccione, R., Ropeleski, M., Singh Salh, B., Lukas, M., Colombel, J. F., Allez, M., Desreumaux, P., Dupas, J. L., Grimaud, J. C., Hebuterne, X., Laharie, D., Lerebours, E., Peyrin Biroulet, L., Reimund, J. M., Viennot, S., Zerbib, F., Antoni, C., Atreya, R., Baumgart, D. C., Berg, C., Boecker, U., Bramkamp, G., Bünning, C., Ehehalt, R., Howaldt, S., Kucharzik, T., Lamprecht, H. G., Mudter, J., Preiss, J. C., Schreiber, S., Seidler, U., Altorjay, I., Banai, J., Lakatos, P. L., Varga, M., Vincze, A., Avni Biron, I., Fishman, S., Fraser, G. M., Goldin, E., Rachmilewitz, D., Annese, V., Ardizzone, S., Biancone, L., Bossa, F., Danese, S., Fries, W., Gionchetti, P., Maconi, G., Terrosu, G., Usai, P., D'Haens, G. R., Gearry, R. B., Hill, J., Rowbotham, D. S., Schultz, M., Stubbs, R. S., Wallace, D., Walmsley, R. S., Wyeth, J., Malecka Panas, E., Paradowski, L., Regula, J., Beales, I. P., Campbell, S., Hawthorne, A. B., Parkes, M., Travis, S. P., Achkar, J. P., Behm, B. W., Bickston, S. J., Brown, K. J., Chiorean, M. V., Devilliers, W. J. S., Elliott, D. E., Grunkmeier, D., Hamilton, J. W., Hanauer, S. B., Hanson, J. S., Hardi, R., Helper, D. J., Herfarth, H., Higgins, P. D. R., Holderman, W. H., Kottoor, R., Kreines, M. D., Leman, B. I., Li, X., Loftus, E. V., Noar, M., Oikonomou, I., Onken, J., Peterson, K. A., Phillips, R. P., Randall, C. W., Ricci, M., Ritter, T., Rubin, D. T., Safdi, M., Sandborn, W. J., Sauberman, L., Scherl, E., Schwarz, R. P., Sedghi, S., Shafran, I., Sninsky, C. A., Stein, I., Swoger, J., Vecchio, J., Weinberg, D. I., Wruble, L. D., Yajnik, V., and Younes, Z.
- Subjects
Adult ,Male ,musculoskeletal diseases ,medicine.medical_specialty ,Colon ,medicine.medical_treatment ,Colonoscopy ,Klinikai orvostudományok ,Placebo ,law.invention ,Anti-TNF ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Double-Blind Method ,Gastrointestinal Agents ,Randomized controlled trial ,Ileum ,Recurrence ,law ,CDAI ,Inflammatory Bowel Disease ,PREVENT ,Gastroenterology ,Secondary Prevention ,medicine ,Clinical endpoint ,Humans ,Postoperative Period ,Colectomy ,Gastrointestinal agent ,Hepatology ,medicine.diagnostic_test ,business.industry ,Orvostudományok ,Middle Aged ,Crohn's Disease Activity Index ,Infliximab ,Surgery ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Background & Aims Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence. Methods We evaluated the efficacy of infliximab in preventing postoperative recurrence of CD in 297 patients at 104 sites worldwide from November 2010 through May 2012. All study patients had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) to groups given infliximab (5 mg/kg) or placebo every 8 weeks for 200 weeks. The primary end point was clinical recurrence, defined as a composite outcome consisting of a CD Activity Index score >200 and a ≥70-point increase from baseline, and endoscopic recurrence (Rutgeerts score ≥i2, determined by a central reader) or development of a new or re-draining fistula or abscess, before or at week 76. Endoscopic recurrence was a major secondary end point. Results A smaller proportion of patients in the infliximab group had a clinical recurrence before or at week 76 compared with the placebo group, but this difference was not statistically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confidence interval: -1.3% to 15.5%; P =.097). A significantly smaller proportion of patients in the infliximab group had endoscopic recurrence compared with the placebo group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95% confidence interval: 18.6% to 40.2%; P
- Published
- 2016
48. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure
- Author
-
Gerasimos Filippatos, Pim van der Harst, Jozine M. ter Maaten, F. Zannad, Stefan D. Anker, Chim C. Lang, Kenneth Dickstein, Aeilko H. Zwinderman, Nilesh J. Samani, Adriaan A. Voors, John G.F. Cleland, Hans L. Hillege, Marco Metra, Leong L. Ng, Piotr Ponikowski, Dirk J. van Veldhuisen, Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), Groningen Kidney Center (GKC), APH - Amsterdam Public Health, Epidemiology and Data Science, Royal Brompton & Harefield NHS Foundation Trust, and National Institute for Health Research
- Subjects
Male ,Proteomics ,Cardiac & Cardiovascular Systems ,Angiotensin-Converting Enzyme Inhibitors ,BLOOD-PRESSURE ,030204 cardiovascular system & hematology ,Treatment response ,COLLABORATION ,THERAPY ,Heart failure ,Individualized treatment ,Systems biology ,0302 clinical medicine ,Furosemide ,Cause of Death ,Outpatient clinic ,030212 general & internal medicine ,Prospective Studies ,Precision Medicine ,Prospective cohort study ,Diuretics ,Cause of death ,Mineralocorticoid Receptor Antagonists ,Aged, 80 and over ,Evidence-Based Medicine ,Genomics ,ASSOCIATION ,Middle Aged ,EUROPEAN-SOCIETY ,3. Good health ,Europe ,Hospitalization ,Practice Guidelines as Topic ,Disease Progression ,Female ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,medicine.medical_specialty ,Adrenergic beta-Antagonists ,BIOMARKERS ,ESC ,1102 Cardiovascular Medicine And Haematology ,03 medical and health sciences ,Angiotensin Receptor Antagonists ,medicine ,Humans ,Mortality ,Intensive care medicine ,ROSUVASTATIN ,Aged ,Science & Technology ,business.industry ,Evidence-based medicine ,Precision medicine ,medicine.disease ,Blood pressure ,Cardiovascular System & Hematology ,Chronic Disease ,PERSONALIZED MEDICINE ,Cardiovascular System & Cardiology ,business ,Heart failure with preserved ejection fraction ,Genome-Wide Association Study ,TASK-FORCE - Abstract
Aims: \ud \ud Despite major improvements in pharmacological and device treatments, heart failure remains a syndrome with high morbidity and mortality, poor quality of life, and high health-care costs. Given the extensive heterogeneity among patients with heart failure, substantial differences in the response to therapy can be expected. We hypothesize that individualized therapy is an essential next step to improve outcomes in patients with heart failure.\ud Methods: \ud \ud The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) included 2516 patients with worsening signs and/or symptoms of heart failure from 11 European countries, who were considered to be on suboptimal medical treatment. Another 1738 patients from Scotland were included in a validation cohort. Overall, both patient cohorts were well matched. The majority of patients were hospitalized for acute heart failure, and the remainder presented with worsening signs and/or symptoms of heart failure at outpatient clinics. Approximately half of the patients were in New York Heart Association class III, and 7% vs 34% of patients of the index vs validation cohort had heart failure with preserved ejection fraction. According to study design, all patients used diuretics, but owing to the inclusion criteria of both cohorts, patients were not on optimal, evidence-based medical therapy. In the follow-up phase, uptitration to guideline-recommended doses was encouraged.\ud Conclusion: \ud \ud By using a novel systems biology approach, incorporating demographics, biomarkers, genome-wide analysis, and proteomics, a model that predicts response to therapy will be developed, which should be instrumental in developing alternative therapies for patients with suboptimal response to currently recommended therapies and thus further improve care for patients with heart failure.
- Published
- 2016
49. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial
- Author
-
Hessel Wijkstra, Matthijs J. Scheltema, M. Pilar Laguna, Daniel M. de Bruin, Willemien van den Bos, Jean J.M.C.H. de la Rosette, Theo M. de Reijke, Graduate School, Urology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Biomedical Engineering and Physics, APH - Amsterdam Public Health, Signal Processing Systems, and Biomedical Diagnostics Lab
- Subjects
Ablation Techniques ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Biopsy ,030232 urology & nephrology ,Ablation ,urologic and male genital diseases ,SDG 3 – Goede gezondheid en welzijn ,law.invention ,03 medical and health sciences ,Prostate cancer ,Study Protocol ,0302 clinical medicine ,Randomized controlled trial ,SDG 3 - Good Health and Well-being ,law ,Prostate ,Focal therapy ,Irreversible electroporation ,Genetics ,medicine ,Humans ,Aged ,business.industry ,Cancer ,Prostatic Neoplasms ,Middle Aged ,Localized ,Neurovascular bundle ,medicine.disease ,Surgery ,Prostate-specific antigen ,medicine.anatomical_structure ,Electroporation ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,IRE ,Radiology ,Neoplasm Grading ,business - Abstract
Background: Current surgical and ablative treatment options for prostate cancer (PCa) may result in a high incidence of (temporary) incontinence, erectile dysfunction and/or bowel damage. These side effects are due to procedure related effects on adjacent structures including blood vessels, bowel, urethra and/or neurovascular bundle. Ablation with irreversible electroporation (IRE) has shown to be effective and safe in destroying PCa cells and also has the potential advantage of sparing surrounding tissue and vital structures, resulting in less impaired functional outcomes and maintaining men's quality of life. Methods/Design: In this randomized controlled trial (RCT) on IRE in localized PCa, 200 patients with organ-confined, unilateral (T1c-T2b) low- to intermediate-risk PCa (Gleason sum score 6 and 7) on transperineal template-mapping biopsies (TTMB) will be included. Patients will be randomized into focal or extended ablation of cancer foci with IRE. Oncological efficacy will be determined by multiparametric Magnetic Resonance Imaging, Contrast-Enhanced Ultrasound imaging if available, TTMP and Prostate Specific Antigen (PSA) follow-up. Patients will be evaluated up to 5 years on functional outcomes and quality of life with the use of standardized questionnaires. Discussion: There is critical need of larger, standardized RCTs evaluating long-term oncological and functional outcomes before introducing IRE and other focal therapy modalities as an accepted and safe therapeutic option for PCa. This RCT will provide important short- and long-term data and elucidates the differences between focal or extended ablation of localized, unilateral low- to intermediate-risk PCa with IRE. Trial registration: Clinicaltrials.gov database registration number NCT01835977. The Dutch Central Committee on Research Involving Human Subjects registration number NL50791.018.14.
- Published
- 2016
50. Symptomatic and Asymptomatic Colon Cancer Recurrence: A Multicenter Cohort Study
- Author
-
Willem A. Bemelman, Laura A M Duineveld, Pieter J. Tanis, Henk van Weert, Jan Wind, Kristel M. van Asselt, Anke B. Smits, General practice, Graduate School, APH - Amsterdam Public Health, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, and ACS - Amsterdam Cardiovascular Sciences
- Subjects
Adult ,Male ,medicine.medical_specialty ,Abdominal pain ,Colorectal cancer ,Colonoscopy ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,030212 general & internal medicine ,Original Research ,Aged ,Netherlands ,Retrospective Studies ,Ultrasonography ,Tumor marker ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Carcinoma ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Abdominal Pain ,Surgery ,Survival Rate ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Cohort ,Female ,Neoplasm Recurrence, Local ,medicine.symptom ,Tomography, X-Ray Computed ,Family Practice ,business ,Follow-Up Studies ,Cohort study - Abstract
PURPOSE Follow-up after colorectal cancer treatment with curative intent aims to detect recurrences and metachronous tumors in a timely manner. The objective of this study is to assess how recurrent disease presents and is diagnosed within scheduled follow-up according to the national guideline for the Netherlands. METHODS In a retrospective study of consecutive patients with colorectal cancer who were treated in 2 hospitals in the Netherlands, we identified patients with colon cancer who underwent surgery with curative intent between January 2007 and December 2012. Patients who developed recurrent disease were included for further analyses. RESULTS From a total of 446 patients who were been treated for colon carcinoma with curative intent, 74 developed recurrent disease (17%). In 43 of those patients (58%), recurrent disease was detected during a scheduled follow-up visit, with 41 (95%) being asymptomatic. Tumor marker testing, imaging, and colonoscopy identified all of these recurrences. In the remaining 31 patients with recurrent disease (42%), recurrence was found during non-scheduled interval visits; 26 (84%) of these patients were symptomatic. The most prevalent symptoms were abdominal pain, altered defecation, and weight loss. Patients with asymptomatic recurrences had a significantly higher overall survival compared with patients with symptomatic recurrences. CONCLUSIONS In this cohort, 42% of the recurrences after initial curative treatment for colon cancer were found during non-scheduled interval visits, mainly based on symptoms. Primary care physicians who take care of patients whose colon cancer might recur should be aware of the relatively high rate of symptomatic recurrences and of typical presenting symptoms.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.